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ABSTRACT 
 
The microtubule associated protein 1 S (MAP1S) is the shortest member of the 
mammalian MAP1 family of proteins. In contrast to MAP1A and MAP1B, which 
are predominantly expressed in the nervous system, MAP1S is expressed in a 
wide range of tissues with the highest protein levels in brain and testis. All 
MAP1 proteins are synthesized as precursor proteins and then cleaved into a 
heavy and a light chain. MAP1S is partially cleaved in a tissue specific manner. 
As light chains of MAP1 proteins bind to both, microtubules and filamentous 
actin, MAP1S (as all the other members of the family) might act as crosslinker 
protein between microtubules and actin filaments. Other potential interaction 
partners of MAP1S (the testis-specific VCY2 protein, the fibroblast growth factor 
receptor associated protein LRPPRC, and the tumour suppressor protein 
RASSF1A) suggest functions of MAP1S in spermatogenesis, chromosome 
remodelling, cytokinesis, apoptosis, and tumourigenesis. 
In the first part of my thesis I looked at interactions between MAP1 proteins and 
posttranslational modifications of MAP1S in comparison to MAP1B and MAP1A. 
I found that all members of the MAP1 family can take part in heterotypic 
complexes formed between heavy and light chains probably via domains 
conserved in all three MAP1 members. In contrast to MAP1B, the potential S-
nitrosylation of MAP1S does not influence its microtubule binding ability. 
Moreover, MAP1S, unlike MAP1B, is not modified by N-ε-lysine acetylation.  
In the second and major part of my thesis I investigated the role of MAP1S in 
vivo by generating MAP1S deficient mice. Since MAP1S is ubiquitously 
expressed and might play a role in mitosis, I decided to generate conditional 
knockout mice to avoid the potential embryonic lethality of a homozygous 
MAP1S deletion. Surprisingly, I found that homozygous MAP1S knockout mice 
are viable and fertile and show no overt phenotype. Histological analysis 
showed no obvious abnormalities in brain or other organs, except for a 
disturbed organisation of bile ducts in the liver in one MAP1S knockout mouse. 
Cultured MAP1S deficient primary neurons displayed a shift from one to two 
axons per cell body, indicating a role of MAP1S in neurotigenesis. Cultured 
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fibroblasts revealed a crucial role of MAP1S in cell cycle progression and 
migration.  
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ZUSAMMENFASSUNG   
 
Das Mikrotubuli assoziierte Protein 1 S (MAP1S) ist das kleinste Mitglied der 
MAP1 Proteinfamilie in Säugetieren. Im Gegensatz zu MAP1A und MAP1B, die 
vorwiegend im Nervensystem exprimiert werden, wird MAP1S in vielen 
verschiedenen Geweben exprimiert, mit dem höchsten Expressionslevel in 
Gehirn und Testes. Alle MAP1 Proteine werden als Precursor-Proteine 
translatiert und dann in eine schwere und eine leichte Kette gespalten. Die 
Spaltung von MAP1S ist gewebespezifisch. Da die leichte Kette der MAP1 
Proteine sowohl an Mikrotubuli als auch an filamentöses Aktin binden, stellt 
MAP1S (sowie alle anderen MAP1 Proteinfamilienmitglieder) wahrscheinlich 
eine Verbindung zwischen Mikrotubuli und Aktinfilamenten her. Andere 
potentielle Interaktionspartner von MAP1S (das testisspezifische Protein VCY2, 
das Fibroblastenwachstumsfaktorrezeptor assoziierte Protein LRPPRC und das 
Tumorsuppressorprotein RASSF1A) lassen darauf schließen, dass MAP1S 
während der Spermatogenese, des Chromosomenremodelling, der Zytokinese, 
der Apoptose und der Tumorentstehung eine große Rolle spielt.  
Im ersten Teil meiner Dissertation untersuchte ich Interaktionen zwischen 
MAP1 Proteinen und posttranslationale Veränderungen von MAP1S im 
Vergleich zu MAP1B und MAP1A. Ich entdeckte, dass alle Mitglieder der MAP1 
Familie miteinander heterotypische Komplexe bilden. Die Proteine interagieren 
wahrscheinlich über konservierte Domänen miteinander. Im Gegensatz zu 
MAP1B verändert eine potentielle Nitrosylierung von MAP1S nicht die Fähigkeit 
von MAP1S an Mikrotubuli zu binden. Außerdem wird MAP1S im Gegensatz zu 
MAP1B nicht N-ε-Lysin-azetyliert.  
Im zweiten und wichtigsten Teil meiner Dissertation habe ich die funktionelle 
Rolle von MAP1S in vivo untersucht, indem ich eine Mauslinie etabliert habe, 
welcher MAP1S fehlt. Da MAP1S ubiquitär exprimiert wird und in Verdacht steht 
eine Rolle während der Zellteilung zu spielen, entschied ich mich eine 
konditionelle Knockoutmaus herzustellen um das Risiko der embryonalen 
Lethalität einer homozygoten MAP1S Deletion zu umgehen. 
Überraschenderweise fand ich, dass homozygote MAP1S Knockoutmäuse 
überlebensfähig und fertil sind und keinen offensichtlichen Phenotyp zeigen. 
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Histologische Analysen zeigten keine Abnormalitäten im Gehirn oder in anderen 
Organen mit Ausnahme von veränderter Organisation der Gallengänge in der 
Leber in einer der drei untersuchten MAP1S Knockoutmäusen. Kultivierte 
primäre Neuronen von MAP1S Knockoutmäusen zeigten einen Wechsel von 
einem zu zwei Axonen pro Zellkörper. MAP1S scheint daher eine Rolle in der 
Neuritogenese zu spielen. Kultivierte primäre Fibroblasten zeigten, dass 
MAP1S während des Zellzyklus und der Zellmigration eine bedeutende Rolle 
spielt.  
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INTRODUCTION  
 
THE CYTOSKELETON 
 
The cytoskeleton is a remarkable system of filaments throughout the cytoplasm.  
On the one hand it forms stable structures and helps cells to establish their 
shape and to be physically robust, on the other hand the cytoskeleton is highly 
dynamic and adapts to changing circumstances. As stable structure, the 
cytoskeleton provides a scaffold to support the plasma membrane and to 
structure the cytoplasm. This scaffold provides the eukaryotic cell with 
mechanical stability and forms stable specialised cell surface protrusions like 
microvilli or cilia. The cytoskeleton is also responsible for large-scale cellular 
polarity and the maintenance of strong intercellular adhesive contacts. The 
dynamic of the cytoskeleton allows cells to change their shape and to rearrange 
their internal components as they grow, divide and adapt to changing 
circumstances. It separates chromosomes during mitosis and meiosis and 
guides the intracellular traffic of organelles. Additionally it enables cells, such as 
fibroblasts, to crawl across surfaces and others, such as sperms, to swim. Due 
to a functioning cytoskeleton, muscle cells are able to contract and nerve cells 
can extend axons and dendrites.  
Most animal cells have three types of cytoskeletal filaments: intermediate 
filaments, actin filaments, and microtubules (figure 1). Additionally, hundreds of 
different cytoskeleton associated accessory proteins are essential for the 
regulation of the spatial distribution and the dynamic behaviour of the 
cytoskeletal filaments.  
 
Intermediate filaments 
 
Intermediate filaments are expressed in some metazoans, including molluscs, 
nematodes, and vertebrates, but they are not present in every cell type. 
Intermediate filaments are mainly found in the cytoplasm of cells that are 
subject to mechanical stress.  
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Figure 1. Organisation of the cytoskeleton in polarised epithelial cells that line 
the small intestine (© Garland Science 2008, Alberts B., 2008).  
 
Regarding their structure, intermediate filaments are rope like fibres with a 
diameter of around 10nm. The individual polypeptides of intermediate filaments 
are molecules with an extended central α-helical domain that form a parallel 
coiled coil with another monomer. Two of these dimers associate in an 
antiparallel fashion to form a tetramer. This tetramer forms the soluble subunit 
of intermediate filaments, which has, in contrast to the subunits of actin 
filaments and microtubules, no nucleoside triphosphate binding site. The 
subunits pack together laterally to build the filament, which includes eight 
parallel protofilaments made up of tetramers. Therefore, each individual 
intermediate filament consists of 32 individual α-helical coils. Many intermediate 
filaments further bundle themselves by self-association, others are held 
together by accessory proteins such as filaggrin or plectin. Intermediate 
filaments are easy to bent, but hard to break.  
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In contrast to the conserved central α-helical domain, the N- and C-terminal 
globular domain can vary to a great extent resulting in various types of 
intermediate filament proteins: nuclear, vimentin-like, epithelial and axonal 
types. Nuclear filaments like the lamins A, B, and C form the nuclear lamina, a 
meshwork beneath the inner nuclear membrane. Vimentin-like intermediate 
filaments consist of vimentin, desmin, glial fibrillary acidic protein, and 
peripherin. Whereas vimentin is found in many cells of mesenchymal origin, 
desmin is expressed only in muscles. Glial fibrillary acidic proteins are located 
in glia cells, peripherin is found in some neurons. Epithelial intermediate 
filaments, keratin type I and type II, are found in epithelial cells and their 
derivates like hair and nails. They provide mechanical strength to epithelial 
tissues through adhesive structures like desmosomes and hemidesmosomes. 
Axonal types of intermediate filaments like neurofilaments are expressed 
predominantly along the axons of vertebrate neurons. The level of 
neurofilament gene expression controls the axonal diameter, which influences 
the speed of signal propagation in the axon.  
 
Actin filaments 
 
In contrast to intermediate filaments, actin is strongly conserved in evolution 
and is found in all cells. Actin filaments, also known as microfilaments, are 
distributed throughout the whole cell with the highest concentration beneath the 
plasma membrane, called the cell cortex, to provide strength and shape to the 
cell and to form cell surface projections. Specialised actin structures enable for 
example fibroblasts to crawl across a surface. During mitosis those structures 
disassemble to round up the cell and actin and its associated motor protein 
myosin then form a belt around the middle of the cell, the contractile ring, which 
divides the cell in two.  
Actin filaments are two-stranded helical polymers formed by globular actin 
monomers with a diameter of 5-9nm. In animal cells, actin filaments are 
organised into bundles or web-like (gel-like) networks. Nucleating proteins, like 
formins, induce the formation of actin bundles. The ARP complex catalyses the 
formation of web-like networks and is associated with structures at the leading 
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edge of migrating cells. External signals can regulate the nucleation of actin 
filaments in the cell cortex to change the cells shape and stiffness rapidly in 
response. Once nucleated, actin filaments generally elongate by the addition of 
soluble subunits. Straight, unbranched filaments can be cross-linked by other 
proteins to form parallel bundles.  
The regular and parallel orientation of their subunits gives actin filaments a 
structural polarity. The two ends of the polymer show different dynamic 
behaviour, with the plus end exhibiting higher polymerisation and 
depolymerisation rates than the minus end. Each actin subunit has a binding 
site for the nucleotide ATP or ADP. On actin filaments, the ATP-binding cleft on 
the monomer points towards the minus end. If the ATP hydrolysis upon 
incorporation into the filament is not as fast as the addition of new subunits, an 
“ATP-cap” can be created on the plus end. On the minus end, ATP-bound actin 
subunits are added more slowly so that the ATP becomes hydrolysed to ADP 
before a new subunit is added. In this way an ATP-bound plus end and an ADP-
bound minus end are generated. Individual filaments have a very short lifetime, 
because the cycle of actin polymerisation and disassembly in cells is extremely 
rapid. During the formation of cellular protrusions a phenomenon called 
treadmilling is very important: monomers are added at the plus end and 
removed at the minus end at the same speed, so the overall polymer length 
remains stable.  
In most nonmuscle vertebrate cells the soluble monomer concentration of actin 
is rather high, but thymosin and other proteins bind to actin monomers and 
prevent them from associating to actin filaments and from hydrolysing or 
exchanging their bound nucleotide. Another monomer binding protein, profilin, 
can recruit actin to filaments. By binding to the actin monomer opposite the 
ATP-binding cleft, the side on the monomer that binds to the plus end, but not 
the side that binds to the minus end, is free. Profilin also binds to acidic 
membrane phospholipids at the cytosolic face of the plasma membrane and can 
be activated by extracellular signals to produce explosive local actin 
polymerisation and to build actin-rich motile structures, such as filopodia and 
lamellipodia. Actin-severing proteins are mostly members of the gelsolin 
superfamily, whose severing activity is activated by high levels of cytosolic 
Ca2+, but requires no extra energy input. 
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As mentioned above, actin is extraordinarily well conserved. Actin sequences 
are about 90% identical among eukaryotes. However, there are small variations 
that can cause significant functional differences. There are three subtly different 
isoforms of actin in vertebrates, termed α, β, and γ-actin. Whereas α-actin is 
expressed only in muscle cells, β and γ-actin are found together in almost all 
nonmuscle cells.  
 
Microtubules 
 
Like actin filaments, microtubules are found in all cells. Microtubules are long, 
hollow cylinders that are often found emanating from the centre in a star-like 
cytoplasmic array in interphase cells. For cell division, the microtubule network 
is rearranged to form the bipolar mitotic spindle. Additionally, they build motile 
structures like cilia and flagella on the cell surface and are aligned to bundles in 
neuronal axons that serve as transport tracks. When epithelial cells form cell-
cell junctions and become highly polarised, the microtubule minus ends move to 
a region near the apical plasma membrane and an array of nearly parallel 
microtubules forms along the long axis of the cell, with plus ends extending as 
far as the basal surface. 
Structurally, microtubules are long, hollow cylinders with an outer diameter of 
25nm formed from protein subunits of tubulin. Like actin, tubulin is a highly 
conserved protein. The tubulin subunit itself is a heterodimer made of two 
closely related globular proteins called α-tubulin and β-tubulin, tightly bound 
together by noncovalent bonds. Each α or β monomer has a binding site for one 
molecule of GTP. Whereas the GTP on α-tubulin is physically trapped and 
never hydrolysed, the nucleotide on the β-tubulin is exchangeable. 13 parallel 
tubulin protofilaments form the hollow cylindrical structure of a microtubule. Due 
to strong longitudinal and comparatively weak lateral contacts among subunits, 
microtubules are more rigid than actin filaments, but they break easier than 
intermediate filaments when they are bent. Each protofilament in a microtubule 
points in the same direction giving microtubules structural polarity. Like in actin 
filaments, the end of the filament, where both growth and shrinkage are fast, is 
called the plus end, and the other end is called the minus end. On microtubules, 
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α subunits are exposed at the minus end, and β subunits are exposed at the 
plus end.  
In mammalians there are at least six forms of α-tubulin and a similar number of 
forms of β-tubulin, each encoded by a different gene. Despite their similarity, 
they have distinct locations in a cell and perform slightly different functions. For 
example, γ-tubulin is involved in the nucleation of microtubule growth from the 
microtubule organising centre (MTOC). In most animal cells a single, well 
defined MTOC called the centrosome is located near the nucleus. The 
centrosome consists of a fibrous centrosome matrix containing over fifty copies 
of γ-tubulin ring complex (γ-TuRC) and a pair of cylindrical structures called 
centriols, which organise the centrosome matrix and ensure its duplication at 
each cell cycle as the centriols themselves duplicate. In animal cells, the astral 
configuration of microtubules is very robust, with dynamic plus ends pointing 
outward toward the cell periphery and stable minus ends collected near the 
nucleus.  
The ends of microtubules are large and complex structures and therefore they 
provide many possibilities for accessory proteins. Some of them are simple 
capping proteins, others, like certain kinesin-related proteins are known as 
catastrophe factors, because they significantly increase the catastrophe rate, 
where microtubules change from a state of polymerisation to one of 
depolymerisation. The protein katanin is required for severing a microtubule. 
Katanin has to break thirteen longitudinal bonds and therefore requires ATP. It 
is made up of two subunits, the smaller subunit hydrolyzes ATP and performs 
the actual severing, and the larger one directs katanin to the centrosome. 
Katanin releases microtubules from their attachment on the MTOC and plays 
probably an important role in the rapid microtubule depolymerisation at the 
spindle poles during meiosis and mitosis. It may also be involved in microtubule 
release and depolymerisation in proliferating cells in interphase and in 
postmitotic cells such as neurons (Alberts B., 2008).  
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MICROTUBULE ASSOCIATED PROTEINS 
 
Proteins that bind along the sides of microtubules are collectively called 
microtubule associated proteins (MAPs). This diverse family of proteins plays 
an important role for the function of microtubules. Members of the MAP family 
were first classified according to their molecular weight, as revealed by SDS-
PAGE, later according to their molecular structure and function (Schoenfeld and 
Obar, 1994; Wiche et al., 1991).  
Due to their molecular structure and function, MAPs are grouped in three 
classes. The first class consists of proteins called structural MAPs, or simply 
MAPs. They bind to, stabilise and promote the assembly of microtubules and 
they copurify with tubulin during cycles of temperature-dependent microtubule 
assembly and disassembly. Members of this class are the MAP1 and MAP2 
families and will be discussed later on in more detail. The second class includes 
proteins which are often found associated with microtubules, but they are 
normally not called MAPs at all. Examples are glycolytic enzymes (like 
GAPDH), kinases (like protein kinase A), proteins involved in biosynthesis (like 
elongation factor EF-1α), proteins linking microtubules to membrane receptors 
(like dynamin), and ribonucleoproteins containing mRNA. The third class of 
proteins is also known as motor proteins. These proteins generate movement 
along microtubules using chemical energy of ATP hydrolysis. Well known 
representatives of this class are kinesin and dynein. These proteins can bind 
tightly to microtubules, but they do not copurify through cycles of assembly and 
disassembly (Mandelkow and Mandelkow, 1995).  
As mentioned above, proteins of the first class of MAPs, the structural MAPs, 
are divided into two families, namely the MAP2/Tau family and the MAP1 family. 
More specifically, the mammalian MAP2/Tau family members are MAP2, Tau, 
and MAP4. Whereas MAP2 and Tau are expressed predominantly in neurons, 
MAP4 is found in a wide range of tissues, but not in neurons. Possible functions 
of these proteins are stabilising microtubules, regulating microtubule networks 
in axons and dendrites of neurons, binding to filamentous (F) actin, recruitment 
of signalling proteins and regulation of microtubule-mediated transport. Tau is 
also implicated in dementias like Alzheimer’s disease. Knockout experiments in 
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mice revealed that neither MAP2 nor Tau are essential for normal brain 
morphology, but the microtubule density was reduced in dendrites and in small-
calibre axons in MAP2 and in Tau knockout mice, respectively. In addition, the 
dendrite length in cultured neurons from MAP2 knockout mice was reduced. 
The non-neuronal member of this family, MAP4, seems to play a role in the 
regulation of microtubule dynamics during metaphase, but as one component of 
a functionally redundant system (Dehmelt and Halpain, 2005).  
 
MAP1 family proteins 
 
Most vertebrate genomes (including human, mouse and rat) contain three 
MAP1 family members: MAP1A, MAP1B and MAP1S. Two decades ago 
MAP1A and MAP1B were identified and characterised by their ability to bind 
and stabilise microtubules in vertebrate brain. Both high molecular mass 
proteins (~ 300kDa, 2500aa) are expressed predominantly in the nervous 
system and right from the start they were suspected to be involved in axon 
guidance and synaptic function (Drewes et al., 1998; Gonzalez-Billault et al., 
2002; Matus, 1988; Schoenfeld and Obar, 1994; Takei et al., 2000; Wiche et al., 
1991). The third member of the MAP1 family, MAP1S, was discovered and 
characterised only recently (Dallol et al., 2004; Liu et al., 2002; Orban-Nemeth 
et al., 2005; Song et al., 2005; Wong et al., 2004). In contrast, only one family 
member, Futsch, is found in Drosophila.  
Futsch, the Drosophila homologue of the MAP1 family proteins, is about twice 
the size of MAP1B. Futsch and MAP1B show high homology in the N- and C-
terminal domains. Futsch colocalises with microtubules and plays an important 
role in the organisation of the microtubule cytoskeleton during axonal growth 
and synaptogenesis (Gogel et al., 2006). It is involved in progressive 
neurodegeneration and futscholk mutants exhibit several characteristics of 
human neurodegenerative diseases (Bettencourt da Cruz et al., 2005). Like 
MAP1B, Futsch appears to be regulated by phosphorylation of at least one 
conserved phosphorylation site mediated by glycogen synthase kinase 3β 
(GSK3β). While Futsch was previously thought to be expressed as a single 
uncleavable protein (Gogel et al., 2006), a recent study showed that Futsch is 
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cleaved, like MAP1B, into in a heavy (HC) and a light chain (LC), at a 
conserved cleavage site (Zou et al., 2008a).  
 
MAP1A and MAP1B 
 
MAP1A and MAP1B are distantly related high molecular mass proteins. After 
their initial expression as polyprotein precursor, each is cleaved into a LC and a 
HC. By using MAP1B deletion mutants, a cleavage site of the precursor protein 
of MAP1B was predicted, that seems to be conserved in all MAP1 proteins 
(Tögel et al., 1999). The LCs of MAP1A and MAP1B are also called LC2 and 
LC1, respectively. Heavy and light chains assemble into complexes together 
with the separately encoded subunit LC3 (Halpain and Dehmelt, 2006). Not only 
homotypic complexes are formed, meaning that a MAP1A HC is associated with 
a MAP1A LC and a MAP1B HC is associated with a MAP1B LC, but also 
heterotypic complexes (Noiges et al., 2006).  
LC3 is a subunit of MAP1A and MAP1B protein complexes that is encoded by a 
separate gene. Most LC3 molecules bind to microtubules via MAP1A or 
MAP1B. It is proposed that LC3 can regulate the microtubule binding activity of 
MAP1A and MAP1B (Mann and Hammarback, 1994). LC3 is implicated in 
autophagy in mammalian cells as a homologue of Apg8p, an essential protein 
for autophagy in yeast. In rats, LC3 is cleaved and posttranslationally modified 
to generate LC3-I and LC3-II in various cells. LC3-I is cytosolic, whereas LC3-II 
is membrane bound (Kabeya et al., 2000). In humans, three orthologs are 
found, named MAP1LC3A, MAP1LC3B, and MAP1LC3C, which also differ in 
their post-translational modifications (He et al., 2003).  
MAP1A and MAP1B can bind to microtubules via a domain at the N terminus of 
their LCs (Mann and Hammarback, 1994; Noiges et al., 2002; Orban-Nemeth et 
al., 2005). Furthermore, their HCs both contain additional sequences that bind 
microtubules (Cravchik et al., 1994; Noble et al., 1989; Vaillant et al., 1998; 
Zauner et al., 1992). Interestingly, amino acids within these microtubule-binding 
domains are not conserved.  
MAP1B LC induces formation of stable but flexible microtubule bundles that are 
resistant against the effects of taxol and nocodazole. This MAP1B LC activity 
can be inhibited by the MAP1B HC. Therefore the MAP1B HC might act as a 
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regulatory subunit of the MAP1B complex to control LC activity (Tögel et al., 
1998).  
MAP1B and MAP1A can also interact with actin filaments. For binding to actin 
filaments, an F-actin binding domain at the C terminus was identified (Noiges et 
al., 2002). In addition, LCs can dimerise or oligomerise. Domains for the 
interactions between LCs and between LC and HC are homologous between 
MAP1A and MAP1B (Tögel et al., 1998).  
As already mentioned, MAP1A and MAP1B are expressed predominantly in the 
nervous system. The expression is developmentally regulated. In murine brain, 
the expression level of MAP1A is low at birth and then increases over the next 
three weeks, whereas MAP1B expression is already high at birth, increases 
slightly over the next few days and then drops to lower levels. These findings 
suggest that MAP1B regulates the cytoskeleton during neurotigenesis, and 
MAP1A functions in the cytoskeleton in mature neurons (Garner et al., 1990; 
Schoenfeld et al., 1989; Schoenfeld and Obar, 1994). Also in the neurons 
derived from rat retina, MAP1A was not detected until 7 days postnatal (Bates 
et al., 1993; Okabe et al., 1989; Tucker and Matus, 1988). However, studies in 
human foetal brains reveal a different expression pattern. MAP1A is found in 
human foetal brain in the telencephalic proliferative zone and within the internal 
capsule. While MAP1A is expressed between 18 and 22 weeks of gestation, 
MAP1B is found only from the 26th week to the 33 week in the internal capsula. 
Nevertheless, MAP1B is already expressed in early embryonic human spinal 
cord (Riederer, 2007). 
In the nervous system, both proteins, MAP1A and MAP1B, are modified by 
phosphorylation (Avila et al., 1994a). So far, many phosphorylation sites on 
MAP1B have been identified in proteomic studies, but only little is known about 
the function of all these phosphorylation sites (Riederer, 2007).  At least two 
modes of MAP1B phosphorylation could be distinguished by the use of different 
antibodies to phosphorylation-sensitive epitopes so far. The first one, termed 
mode I phosphorylation, is carried out by proline-dependent kinases (PDKs) 
and is found in outgrowing axons and is diminished during brain development. 
The second one, termed mode II phosphorylation, is carried out by the Casein 
Kinase II (CKII) and is found in axons and dendrites and remains into adulthood 
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(Avila et al., 1994b; Diaz-Nido et al., 1988; Gonzalez-Billault et al., 2004; 
Riederer, 2007; Ulloa et al., 1993).   
MAP1B is phosphorylated via signalling kinases, including the glycogen 
synthase kinase-3 β (GSK3β), cdk5, and Jun N-terminal kinase 1 (JNK1) 
(Chang et al., 2003; Del Rio et al., 2004; Goold and Gordon-Weeks, 2003; 
Goold et al., 1999). GSK3β phosphorylates mouse MAP1B at two residues, 
Ser1260 and Thr1265, and is restricted to growing axons with highest levels in 
the distal part. Phosphorylated MAP1B regulates microtubule dynamics by 
maintaining microtubules in growth cones in a dynamically unstable state, which 
is required during path finding (Goold et al., 1999; Johnstone et al., 1997; 
Trivedi et al., 2005). Moreover, the axon guidance cue Netrin 1 controls the 
mode I phosphorylation of MAP1B via GSK3β and CDK5 (Del Rio et al., 2004). 
Another pathway upstream of the activation of GSK3β is the MAPK pathway. 
Partly through the MAPK pathway and the further phosphorylation of MAP1B, 
nerve growth factor (NGF) increases neurite growth rates (Goold and Gordon-
Weeks, 2005). Another kinase that phosphorylates MAP1B is the Jun N-
terminal kinase 1 (JNK1). In JNK1 knockout mice, MAP1B is found to be 
hypophosphorylated, resulting in a compromised ability to bind to microtubules 
and to promote their assembly (Chang et al., 2003). Additionally, contact with 
myelin-associated glycoprotein (MAG) appears to trigger an increase the 
amount of phosphorylated MAP1B in dorsal root ganglia neurons (DRGNs) 
(Franzen et al., 2001). It was shown that, depending on its phosphorylation 
state, MAP1B is transported in the axons of sciatic nerves of adult rats at two 
different rates. The relatively fast transport of phosphorylated MAP1B may be 
responsible for its high concentration in the distal end of growing axons. The 
difference in transport velocity of phosphorylated versus non phosphorylated 
MAP1B is possibly due to the association with different proteins (Ma et al., 
2000).  
Less is known about the regulation of MAP1A. A recent study identified MAP1A 
LC as a substrate for CK1δ, a member of the casein kinase 1 family of 
serine/threonine-specific kinases. Thus, CK1δ may modulate microtubule 
dynamics by changing the phosphorylation status of the MAP1A LC (Wolff et 
al., 2005).  
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MAP1B Gene Targeting studies 
 
To define the role of MAP1B in vivo, MAP1B deficient mice have been 
generated. Four independent research groups have generated mice with 
disrupted MAP1B genes till now. In every mouse line, brain development is 
disturbed, although the severity of the phenotypic effects is quite different in 
these four mouse lines (Edelmann et al., 1996; Gonzalez-Billault et al., 2000; 
Meixner et al., 2000; Takei et al., 1997). Homozygous MAP1B deficient mice 
from Edelmann et al. and González-Billault et al. die during embryogenesis or 
shortly after birth, respectively (Edelmann et al., 1996; Gonzalez-Billault et al., 
2000). Edelmann et al. generated mice which carry an insertion, a neo cassette 
in reverse transcriptional orientation, in exon 5 of the MAP1B gene leading to a 
depletion of the MAP1B protein. Homozygotes die during embryogenesis, 
heterozygotes grow slower, they lack the visual acuity in one or both eyes, and 
they suffer from motor system abnormalities (Edelmann et al., 1996). González-
Billault et al. analysed MAP1B mutant mice generated by a gene trapping 
approach. In these mice, an IRESβgal/neo sequence inserted between exon 2 
and 3 of the MAP1B gene leads to the expression of the β-galactosidase 
marker and the premature termination of MAP1B translation (Chowdhury et al., 
1997; Gonzalez-Billault et al., 2000). Homozygotes die shortly after birth. In 
their brain, lateral ventricles are enlarged, the corpus callosum appears 
interrupted, in the cerebellum the wide band of Purkinje cells is absent and the 
normal laminar organisation in the hippocampus and in the cerebellum is 
disturbed (González-Billault et al., 2000). In contrast, homozygotes from Takei 
et al. and Meixner et al. are viable (Meixner et al., 2000; Takei et al., 1997). 
Homozygotes from Takei et al., in which a neo cassette replaces exon 1 of 
MAP1B still express low levels of a presumably truncated form of MAP1B from 
an alternative promoter, exhibit a slightly decreased brain weight and a delay in 
the development of the nervous system. Cultured neurons obtained from these 
mice show delayed axon outgrowth, a reduced rate of elongations, aberrant 
growth cone formation, and increased actin-based protrusive activity (Takei et 
al., 1997). Homozygotes from Meixner et al., in which exon 3 to 5 of MAP1B are 
deleted, are missing the corpus callosum. The cerebral white matter ends 
medially in a thick bundle of myelinated fibers, resembling the Probst bundle 
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present in agenesis of the corpus callosum. In the peripheral nervous system, 
axonal and myelinisation defects resulting in reduced motor nerve conduction 
velocity are observed (Meixner et al., 2000).  
Reasons for these great phenotypic differences in these four MAP1B deficient 
mouse lines are probably their different genetic backgrounds and differently 
designed knockout strategies. First, the genetic background may have an 
influence on the effect of the loss of MAP1B. For example, mice from Edelmann 
et al. are derived from 129OP2/Ola, a strain that displays axonal guidance 
problems and defects in brain development already in wild-type mice (Wahlsten, 
1982). Therefore, the additional reduction or ablation of MAP1B expression may 
lead to more severe developmental problems (Meixner et al., 2000). 
Interestingly, Takei et al. could show the influence of the genetic background on 
the phenotype of their MAP1B mice: MAP1B knockout mice with a genetic 
background of predominantly C57BL/6J (>93%), instead of a mixed 
background, have a partial postnatal lethality (Takei et al., 2000). Second, 
different knockout strategies may cause these different phenotypes. Takei et al. 
argue that the severely abnormal phenotype in MAP1B deficient mice, 
generated from Edelmann et al., might be caused by expression of a 571 amino 
N-terminal fragment of MAP1B, acting in a dominant-negative fashion rather 
than a loss of function (Meixner et al., 2000; Takei et al., 1997). Mice from Takei 
et al. and González-Billault et al. still contain approximately 5% of the amount of 
MAP1B protein present in their wild-type littermates, therefore these mice are 
deficient in MAP1B gene expression, but they are not null mutant mice. The 
reason for residual MAP1B expression is the use of alternative promoters inside 
the MAP1B gene that drive expression of five prime truncated alternatively 
spliced MAP1B transcripts. Alternative spliced isoforms are expressed 
containing uncoding exon 3A or 3U at their five prime joined to exon 3 of the 
regular transcript. They are expressed at about 1 to 10% of the level of regular 
transcripts (Kutschera et al., 1998; Lien et al., 1994). In the mutants generated 
by Takei et al. and González-Billault et al. have been demonstrated to give rise 
to alternatively spliced isoforms albeit at low level (Gonzalez-Billault et al., 2000; 
Kutschera et al., 1998; Takei et al., 1997). Interestingly, alternative isoforms of 
MAP1B were found in affected brain regions of heterozygous mice from 
Gonzalez-Billault et al. The expression level of this isoforms was low, but higher 
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in the mutants than in the wild-types (Gonzalez-Billault et al., 2000). Meixner et 
al. could show that their targeting strategy prevented the expression of regular 
as well as alternative transcripts of MAP1B, resulting in a complete loss of 
MAP1B (Meixner et al., 2000).    
To elucidate the role of MAP1B in more detail, MAP1B knockout mice from 
Meixner et al. were analysed in several studies. Most of them concentrated on 
dorsal root ganglia neurons (DRGNs), primary sensory neurons which transmit 
somatic and sensory information from peripheral tissues to the spinal cord. 
DRGNs consist only of a cell body and one or more axons, but no dendrites or 
afferent synapses. In contrast to wild-type DRGNs, MAP1B knockout DRGNs 
show enhanced neurite branching and impaired axonal turning behaviour. 
Furthermore, the amount of acetylated microtubules within growth cones was 
reduced, whereas the distribution of tyrosinated and detyrosinated microtubules 
was normal in MAP1B knockout DRGNs (Bouquet et al., 2004). When treated 
with lysophosphatidic acid (LPA), an extracellular signalling phospholipid 
triggering changes in actin distribution and cell morphology, growth cones from 
wild-type DRGNs collapse and retract, whereas axons from MAP1B knockout 
DRGNs do not retract although the growth cones collapse. LPA induces actin 
contraction, but further effects on the microtubules that lead to axon retraction 
appeared to be MAP1B dependent. MAP1B is coupling actin and microtubule 
movements probably via its binding to actin and tubulin (Bouquet et al., 2007). 
Another study revealed that MAP1B is an important component in the S-
nitrosylation dependent signal-transduction pathway that is involved in the 
regulation of the axonal cytoskeleton. Whereas wild-type DRGNs show 
enhanced growth cone retraction after nitric oxide treatment, MAP1B knockout 
DRGNs show no reaction. Cys 2457 in the C terminus of MAP1B is a substrate 
for S-nitrosylation in vivo. The nitrosylation of MAP1B leads to enhanced 
interaction with microtubules. It is proposed that MAP1B acts by inhibiting a 
microtubule- and dynein-based mechanism that normally prevents axon 
retraction (Stroissnigg et al., 2007). Additionally, Schwann cells (SCs) have 
been investigated. In cell migration assays, SCs from MAP1B knockout mice 
migrate slower. The speed of migration was less than half of that of wild-type 
controls. It was shown, that the LPA dependent retraction of SC processes is 
MAP1B dependent (Bouquet et al., 2007).  
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MAP1B knockout mice also show a distinct behavioural phenotype. They lack 
exploring activity in the cage (Meixner et al., 2000) and perform poorly in the 
Morris water maze test. The multiple T-maze tests revealed that MAP1B 
knockout mice are extremely sensitive to starvation. Detailed results of these 
tests indicate that the locomotor activity in MAP1B knockout mice is reduced. 
On the other hand, there are no significant differences in cognitive function and 
memory retention (Pangratz-Fuehrer et al., 2005).          
Double knockout mice with disrupted MAP1B and additionally disrupted Tau or 
MAP2 have been generated (Takei et al., 2000; Teng et al., 2001). For these 
double knockout studies the MAP1B deficient mouse line from Takei et al. was 
used. While this MAP1B knockout mouse line and the Tau knockout mouse line 
are viable and display only minor abnormalities in the nervous system (Harada 
et al., 1994; Takei et al., 1997), double knockout mice show a markedly more 
severe phenotype. These mice are suffering from severe brain defects. Primary 
cultures of hippocampal and cerebellar neurons exhibit inhibited axonal 
elongation, delayed neuronal migration, and suppressed neurite elongation.  
These results indicate that MAP1B and Tau act in a synergistic fashion, 
especially as regulators of microtubule organisation in axonal elongation and 
neuronal migration (Takei et al., 2000). Furthermore, MAP2 and MAP1B seem 
to act in a synergistic way as well. While MAP2 deficient mice are viable and 
display no apparent abnormalities, double knockout mice died perinatal. Their 
cerebral cortex is disorganised, showing an “inside-out” pattern in their cortical 
layer. A dispersed arrangement of cell layers is also found in the hippocampus. 
The olfactory bulb and the cerebellum exhibit disrupted laminar structures (Teng 
et al., 2001).   
 
The role of MAP1B in human diseases 
 
MAP1B plays a role in several human neurodegenerative diseases like 
Alzheimer’s disease, Parkinson’s disease, giant axonal neuropathy, fragile X 
syndrome and spinocerebellar ataxia type 1.  
Alzheimer’s disease, an age-related neurodegenerative disorder, is 
characterised by plaques of aggregated β-amyloid peptides, neurofibillary 
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tangles, and neuronal loss in affected brains. It was shown that β-amyloid 
peptide can bind to the HC of MAP1B (Gevorkian et al., 2008). 
Contradicting results exist how accumulative β-amyloid peptides alter MAP1B 
expression. One study shows that β-amyloid peptides induce MAP1B mRNA 
transcription, especially the alternative transcript containing exon 3U. The 
resulting overexpression of MAP1B might act as an effector of cell death 
(Uchida, 2003). Another study finds that β-amyloid peptides lead to a time-
dependent degradation of MAP1B resulting from the β-amyloid-mediated 
activation of caspase-3 and calpain (Fifre et al., 2006). Supporting this study, 
MAP1B is found downregulated in affected brain regions compared to 
unaffected regions in samples taken post-mortem from patients (Yokota et al., 
2006).   
Parkinson’s disease, another neurodegenerative disorder, is characterised by 
Lewy bodies, intraneuronal inclusions comprising α-synuclein-containing 
filaments. MAP1B was found in around 80% of cortical Lewy bodies. MAP1B 
binds to α-synuclein and may therefore play a general role in the pathogenesis 
of Lewy bodies (Jensen et al., 2000).  
Giant axonal neuropathy (GAN) is an autosomal recessive disorder caused by 
mutations in the GAN gene, which encodes the ubiquitously expressed protein 
gigaxonin. Gigaxonin is necessary for the function and survival of neurons by 
controlling protein degradation. Cytopathologically, GAN is characterised by 
cytoskeletal abnormalities. Gigaxonin can bind directly to the LC of MAP1B. 
Mutations in the GAN gene disrupt this interaction of gigaxonin and MAP1B 
(Ding et al., 2002). Therefore, the cross talk between microtubules and 
intermediate filaments is disturbed (Bomont and Koenig, 2003). Ablation of 
gigaxonin results in a substantial accumulation of MAP1B LC in neurons leading 
to the characteristic cell death in GAN disorder. Reducing MAP1B levels 
significantly improves the survival rate of those neurons (Allen et al., 2005).  
The fragile X syndrome is one of the leading causes of inherited mental 
retardation and is caused by the absence of the fragile X mental retardation 
(FMRP) protein. The lack of FMRP causes misregulation of MAP1B translation 
and a delayed decline of MAP1B expression in the brain of FMRP knockout 
mice. The overexpression of MAP1B leads to increased microtubule instability 
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and seems to be an important underlying factor for the pathogenesis of fragile X 
mental retardation (Lu et al., 2004).  
Spinocerebellar ataxia type 1 belongs to a group of autosomal dominant 
neurodegenerative disorders, in which patients suffer from degeneration of the 
cerebellum, leading to uncoordinated movements. It is caused by trinucleotide 
CAG repeat expansions in the ataxin 1 gene coding for polyglutamine. One 
candidate mediator of ataxin 1 toxicity is the leucin-rich acidic nuclear protein, 
which interacts with MAP1B and modulates the effects of MAP1B on neurite 
extension (Opal et al., 2003).      
 
MAP1S 
 
The microtubule associated protein 1 short, MAP1S, was characterised recently 
as a novel member of the MAP1 family. As its name indicates, MAP1S is rather 
short (~120kDa, 973aa) compared to the high molecular mass proteins MAP1A 
and MAP1B (~300kDa, 2500aa). Like MAP1A and MAP1B, MAP1S is encoded 
by seven exons, but no alternative splicing forms have been found. The 
difference in size is mainly due to differences in the length of exon 5, the other 
exons show hardly any differences concerning length. Like all MAPs, MAP1S 
copurifies with microtubules from murine brain through repeated cycles of 
temperature-induced polymerisation and depolymerisation.  
In contrast to MAP1A and MAP1B, which are expressed mainly in the nervous 
system, MAP1S is widely expressed in mouse tissues, with the highest protein 
levels in brain and testis. Like MAP1A and MAP1B, MAP1S is synthesised as a 
precursor protein that is cleaved into a HC and a LC. In case of MAP1S, the 
cleavage appears to be regulated in a tissue specific manner. In brain the 
majority of the protein is cleaved. In testis, kidney, and liver the cleaved and 
uncleaved forms were found at approximately equal levels. In heart, lung, and 
spleen MAP1S is found mainly in the uncleaved form. The expression level of 
MAP1S in brain is already high at birth and increases slightly over the first three 
weeks after birth.  
Similar to MAP1A and MAP1B, the HC and LC of MAP1S interact with each 
other. The MAP1S LC can bind to actin filaments through its C terminus. With 
its N-terminal domain it can bind, bundle and stabilise microtubules. The 
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possibility of binding to both, microtubules and actin, suggests that also the LC 
of MAP1S can act as a crosslinker between microtubules and actin filaments. 
The LC alone can bundle microtubules. When the complete MAP1S is 
expressed, microtubule binding is still observed, but microtubule bundling and 
stabilisation are absent, suggesting a regulatory function of the MAP1S HC 
(Orban-Nemeth et al., 2005).  
Between mice and human, 63% of the amino acids of MAP1S are conserved. 
The murine protein contains 86 amino acids less, the majority is located in exon 
5 (Orban-Nemeth et al., 2005). The human homologue of MAP1S is located on 
chromosome 19 and has previously been named C19ORF5. In yeast two-hybrid 
screens C19ORF5 is identified as possible interaction partner of LRPPRC, 
VCY2 and RASSF1A (Dallol et al., 2004; Liu et al., 2002; Liu and McKeehan, 
2002; Wong et al., 2004).  
 
Putative functions of MAP1S 
 
Interaction partners of MAP1S provide indications of putative functions of 
MAP1S. One possible interaction partner of MAP1S is the leucine rich PPR-
motif containing protein, LRPPRC, also called LRP130, a leucine rich protein 
that copurifies with the fibroblast growth factor receptor (Liu et al., 2002; Liu and 
McKeehan, 2002). LRPPRC associates with nuclear and mitochondrial mRNAs 
and is therefore a potential candidate for coordinating nuclear and mitochondrial 
gene expression (Mili and Pinol-Roma, 2003). Two mutations in LRPPRC are 
identified to cause Leigh syndrome, French-Canadian type (LSFC), a human 
cytochrome c oxidase deficiency (Mootha et al., 2003). MAP1S may link 
LRPPRC to microtubules and mitochondria. Liu et al. show that overexpressed 
MAP1S colocalises not only with microtubules, but also with mitochondria and 
may induce perinuclear aggregates of mitochondria. This mitochondrial 
aggregation can result in degradation of DNA, a cell-death related process 
named mitochondrial aggregation and genome destruction (MAGD) (Liu et al., 
2005a; Liu et al., 2005b). MAP1S may therefore have MAGD activity and play a 
role in apoptosis.   
Due to its interaction with VCY2, MAP1S is also named VCY2 interacting 
protein 1 (VCY2IP-1) (Wong et al., 2004). The exact function of VCY2, which is 
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located in the frequently deleted azoospermia factor c region on the Y 
chromosome, is still unknown, but its impaired expression in infertile men 
suggests an involvement in the pathogenesis of male infertility (Tse et al., 
2003). It has been proposed that VCY2 acts via MAP1S on the microtubule 
network suggesting that both proteins might play an important role in 
spermatogenesis (Wong et al., 2004).  
So far, most information about the potential functions of MAP1S was gained in 
studies on RASSF1A. RASSF1A is an important tumour suppressor protein and 
plays a role in mitosis. As a tumour suppressor protein, RASSF1A is inactivated 
in many types of human cancers by promoter-specific CpG island 
hypermethylation. Overexpression of RASSF1A in several cancer cell lines 
causes drastic reduction of tumourigenicity (Dallol et al., 2004; Dammann et al., 
2003; Rong et al., 2004). RASSF1A knockout mice are significantly tumour-
prone, both for spontaneous tumour formation at an advanced age (18-20 
months) and for chemically induced tumours. Homozygotes and heterozygotes 
show increased tumour multiplicity and tumour size relative to control animals 
(Tommasi et al., 2005). Through interaction with the tumour suppressor protein 
RASSF1A, MAP1S may be involved in tumorigenesis (Dallol et al., 2004). 
Because of its interaction with RASSF1A, MAP1S is also called RABP1 
(RASSF1A binding protein 1) (Song et al., 2005).  
During mitosis, RASSF1A is found on the centrosome and the mitotic spindle 
(Liu et al., 2003; Rong et al., 2004; Song et al., 2004).  Overexpression of 
RASSF1A increases mitotic events with aberrant monopolar spindles, where 
RASSF1A colocalises with these monopolar spindles (Liu et al., 2003). Its 
binding to microtubule is essential for RASSF1A to mediate its growth inhibitory 
effects. After deletion of the microtubule binding sites of RASSF1A, the protein 
was not able to induce growth inhibition and cell death any more (Vos et al., 
2004). Two naturally occurring tumour-associated missense mutants of 
RASSF1A disturb the association of RASSF1A with microtubules. In addition, 
wild-type RASSF1A, but not the two mutants, is able to block DNA synthesis 
(Dallol et al., 2004). Overexpression studies showed that RASSF1A induces 
mitotic arrest at prometaphase, and this arrest is accompanied by the 
accumulation of cyclin A and B. RASSF1A interacts with Cdc20, an activator of 
the anaphase promoting complex (APC), resulting in inhibition of APC 
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activation. Depletion of RASSF1A by using small interfering RNA leads to faster 
degradation of cyclin A and B and mitotic progression as a result of premature 
APC activation. Depletion of RASSF1A also causes cell division defects 
characterised by centrosome abnormalities and multipolar spindles (Song et al., 
2004).  
Through its interaction with RASSF1A, MAP1S is suspected to play a crucial 
role in mitosis and tumourigenesis. Song et al. showed that the overexpression 
of MAP1S increases the abundance of cyclin A and B and leads to an arrest in 
prometaphase in a RASSF1A–dependent manner. MAP1S depletion by siRNA 
accelerates the cell cycle. MAP1S itself is located on the centrosome and it is 
supposed to be required for recruitment of RASSF1A to the spindle poles and 
for its inhibition of APC/Cdc20 activity. In MAP1S-siRNA depleted cells, 
RASSF1A fails to localise to the centrosome during mitosis and no interaction 
between RASSF1A and Cdc20 is found. Although MAP1S is not interacting with 
Cdc20, the recruitment of RASSF1A to spindle poles by MAP1S seems to be 
required for the interaction of RASSF1A with Cdc20 during mitosis. Therefore, 
MAP1S depletion accelerates mitotic progression, but increases the number of 
abnormal mitosis (Song et al., 2005). Contradictory results were obtained by 
Dallol et al.. After MAP1S depletion by siRNA, the level of cyclin B increased 
modestly, cells were able to go through metaphase, but they were not able to 
form a stable metaphase plate with all the chromosomes aligned to it. 
Furthermore, MAP1S depletion caused premature sister chromatid separation 
and multipolar spindles. MAP1S was shown to localise to microtubule-
organising centers (MTOCs). Knockdown of MAP1S resulted in disrupted 
MTOCs and microtubule nucleation from several sites (Dallol et al., 2007).  
A close relative to RASSF1A is NOREA1. MAP1S as well as MAP1B interact 
with NORE1A (Moshnikova et al., 2008). NORE1A is a growth and tumour 
suppressor protein, which is inactivated in a variety of cancers. NORE1A is 
localised to microtubules and centrosomes and this association of NORE1A 
with cytoskeletal elements is suggested to be essential for NORE1A-induced 
growth suppression. Furthermore, the ERK pathway is a target for NORE1A 
growth-suppressive activities (Moshnikova et al., 2006). Moshinova et al. ruled 
out that this localisation is MAP1S dependent (Moshnikova et al., 2008). 
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MAP1S itself was identified as a potential tumour suppressor gene by using a 
modified version of GINI (gene identification by nonsense-mediated decay 
inhibition). With this method, colon cancer cells lines have been screened for bi-
allelic inactivating mutations. Amongst others, MAP1S was identified as a 
candidate tumour suppressor gene (Ivanov et al., 2007). This data supports the 
idea that MAP1S may play a role in tumourigenesis.  
In addition to its potential role in cell cycle progression, MAP1S may regulate 
axonal transport in neurons. Mice deficient in gigaxonin serve as a model for the 
human disorder giant axonal neuropathy (GAN) and show an impaired 
retrograde axonal transport. MAP1S levels are found to be increased in 
gigaxonin null mice. Accumulated MAP1S in cultured wild-type cells alters the 
microtubule network and traps dynein. Finally, this accumulation leads to 
neuronal death in cultured wild-type neurons, replicating the process occurring 
in GAN null mutants (Ding et al., 2006a).  
Another interaction partner of MAP1S is NR3A. The interaction was confirmed 
in vitro and in vivo and binding of MAP1S was localised to the membrane-
proximal part of the NR3A C-terminus. NR3A is a subunit of the N-methyl-D-
aspartate receptor (NMDAR). NMDARs are glutamate-gated ion channels that 
are widely expressed in the nervous system and play a role in excitatory 
synaptic transmission. Most NMDARs consist of two NR1 and two NR2 
subunits. Receptors containing N3A show specific permeation properties and 
seem to play a role in the brain disorder white matter injury (Paoletti and 
Neyton, 2007). NR3A is widely expressed in perisynaptic and extrasynaptic 
sites and appears to be weakly associated with the postsynaptic density. NR3A 
and MAP1S are both found in neurite shafts and occasionally in filopodia-like 
processes. MAP1S may link NR3A to the cytoskeleton and regulate the 
localisation of NR3A-containing receptors at the synapse and regulate their 
movement between synaptic and extrasynaptic sites (Eriksson et al., 2007).  
Recently, human MAP1S was identified as a novel interacting protein of the 
cytokine-induced suppressor of cytokine signalling protein 3 (SOCS3). SOCS3 
is thought to be important for the down regulation of interleukin-6 (IL-6) 
signalling. IL-6 is a proinflammatory cytokine and strongly induces activation of 
STAT1 and STAT3. The phosphorylation of STATs can be inhibited by 
lipopolysaccharide (LPS) induced SOCS3. After MAP1S depletion by siRNA, 
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the inhibition of SOCS3 on STAT3 phosphorylation is partially hindered in the 
presence of IL-6 and LPS, suggesting that the interaction between MAP1S and 
SOCS3 and the integrity of the microtubule cytoskeleton play an important role 
in the negative regulation of SOCS3 on IL-6 signalling (Zou et al., 2008b).  
 
AIMS OF THE THESIS 
 
Since MAP1S was described as a member of the MAP1 family proteins in our 
laboratory, we were interested in the further characterisation of MAP1S by 
biochemical and genetic approaches. Therefore, I set out to analyse 
posttranslational modifications of MAP1S in comparison to MAP1A and MAP1B. 
As the S-nitrosylation of MAP1B leads to enhanced interaction with 
microtubules and leads to axon retraction (Stroissnigg et al., 2007), I wanted to 
investigate the potential S-nitrosylation of MAP1S and its impact on microtubule 
binding. Additionally, I was interested in the potential formation of heterotypic 
complexes formed from all three MAP1 protein subunits. However, the main aim 
of this project was to generate MAP1S deficient mice. By analysing these mice, 
I expected to gain more insight into the in vivo function of MAP1S. MAP1S is 
known to be expressed in all tissues and at all development stages. Therefore, I 
intended to generate conditional knockout mice and to look especially into the 
development of MAP1S knockout mice.  
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PART I – 
POSTTRANSLATIONAL MODIFICATIONS 
OF MAP1S 
IN COMPARISON TO MAP1A AND MAP1B 
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Homotypic and heterotypic complexes of MAP1 proteins  
 
All three MAP1 proteins are synthesised as precursor proteins and cleaved 
posttranslationally into a HC and a LC. Co-immunoprecipitation and co-
purification analyses revealed that the HC and the LC of each protein can form 
a homotypic protein complex (Orban-Nemeth et al., 2005; Schoenfeld et al., 
1989). Additionally, a heterotypic complex consisting of the MAP1B LC and the 
MAP1A HC was found (Kuznetsov et al., 1986; Schoenfeld et al., 1989). 
Furthermore, LCs themselves can oligomerise. It was shown that the MAP1B 
LC can interact with itself and with the LC of MAP1A (Noiges et al., 2006; Tögel 
et al., 1998). To investigate the formation of a heterotypic complex consisting of 
the MAP1B HC and the MAP1A LC, I performed co-immunoprecipitation 
analysis of murine brain. Therefore, brain lysates were immunoprecipitated with 
an antibody against MAP1A LC and analysed by immunoblotting. MAP1A HC, 
as well as MAP1B HC were found in the precipitates (figure 2). Furthermore, the 
reciprocal co-immunoprecipitation was performed (figure 3) to confirm this 
interaction (Noiges et al., 2006).  
 
 
 
 
 
 
 
 
 
Figure 2. MAP1B HC co-immunoprecipitated with the MAP1A LC. Whole brain 
protein lysates of 13-day-old mice (input) were immunoprecipitated (IP) with an 
antibody against the MAP1A LC (anti-MAP1A LC) or without antibody (no ab) 
as negative control. Precipitates were analysed by SDS-PAGE and 
immunoblotting with antibodies against the MAP1B HC (anti-MAP1B HC) or 
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MAP1A HC (anti-MAP1A HC). The position of the respective heavy chain on the 
blot is indicated. A fraction of MAP1B HC present in the lysate was co-
immunoprecipitated with anti-MAP1A LC.  
 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
Figure 3. MAP1A LC co-immunoprecipitated with the MAP1B HC. (A) Whole brain 
protein lysates of 21-day-old mice (input) were immunoprecipitated (IP) with an 
antibody against the MAP1B HC (anti-MAP1B HC), without antibody (no ab) or with an 
antibody against an unrelated protein (chFIP-2; anti-unrelated). Precipitates were 
analysed by SDS-PAGE and immunoblotting with an antibody against the MAP1A LC 
(anti-MAP1A LC) or with the secondary antibody only (no ab). The position of the 
MAP1A LC is indicated. The MAP1A LC was precipitated from brain lysates with the 
antibody against MAP1A LC (anti-MAP1A LC) and co-immunoprecipitated with the 
antibody against MAP1B HC (anti-MAP1B HC). Controls with secondary antibody only 
(no ab) were done to rule out that the MAP1A LC signal after precipitation with MAP1B 
HC was merely due to reaction of the second antibody with the light chain of the 
antibody used in immunoprecipitation which is similar in size to MAP1A LC. (B) 
Approximately 1μg of recombinant MAP1B LC or MAP1A LC were fractionated on 
SDS-PAGE, blotted and probed with amido black to reveal the presence of the two 
proteins on the blot or with anti-MAP1A LC (anti-MAP1A LC). The antibody reacted 
exclusively with MAP1A LC. 
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To identify binding domains, co-transfections and blot overlay analysis using 
recombinant protein domains were performed. Two MAP1 homology (MH) 
domains, namely MH1 and MH3, of MAP1B HC were found to interact with the 
LCs of MAP1B and MAP1A (Noiges et al., 2006; Tögel et al., 1998). The 
interactions between the N terminus of the MAP1B HC and the MH3 domain of 
the MAP1A LC and the MH3 domain of the MAP1B LC were shown recently in 
a yeast 2-hybrid β-galactosidase assay. The interactions of the MAP1A LC with 
the MH3 and the MH1 domains of MAP1B were demonstrated in blot overlay 
assay. Consequently, it was assumed that heterotypic complexes are formed 
due to the binding of the MH1 domain to the MH3 domain (Noiges et al., 2006). 
MH domains are shared by all MAP1 proteins (Langkopf et al., 1992; Noiges et 
al., 2006; Orban-Nemeth et al., 2005). Figure 4 shows the schematic 
representation of MAP1A, MAP1B and MAP1S indicating MH1, 2, and 3.  
 
 
 
MAP1A 
 
 
MAP1B 
 
 
MAP1S 
 
Figure 4. Schematic representation of MAP1 proteins. Grey boxes indicate 
conserved homologous domains (MH1, MH2, and MH3) of MAP1A, MAP1B, and 
MAP1S. Binding sites of the LCs to microtubules (MT) and actin (AC) are indicated. 
The microtubule binding domains are not conserved in sequence. 
 
MAP1S shares these sequence homology domains. Thus, I wanted to 
investigate potential heterotypic interactions including MAP1S. First, potential 
complex formation between MAP1S LC and MAP1B HC were analysed in 
cultured cells. MAP1S LC alone localised on microtubules, the MH1 domain of 
MAP1B alone was distributed diffusely in the cytoplasm. In the presence of 
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MAP1S light chain, the MH1 domain of MAP1B was found to co-localise with 
MAP1S LC on microtubules (figure 5), indicating that the MH1 domain of 
MAP1B could interact with MAP1S LC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. MAP1S LC forms a complex with the MH1 domain of MAP1B HC. PtK2 
cells were transfected with constructs encoding myc-tagged MAP1S LC (MAP1S LC-
myc), HA-tagged MH1 domain of MAP1B HC (MH1B-HA) or co-transfected with both 
constructs. After incubation for 48 hours to allow for protein expression, cells were fixed 
and analysed by triple immunofluorescence microscopy using antibodies against 
tubulin (anti-tubulin), the myc-tag (anti-myc) and the HA-tag (anti-HA). MAP1S LC was 
localised on microtubules, MH1B was diffusely distributed throughout the cytoplasm. In 
the presence of MAP1S LC, MH1B was found to co-localise with MAP1S LC on 
microtubules (arrows). 
 
Next, the potential heterodimer formation of MAP1S LC and MAP1B LC was 
analysed. PtK2 cells were co-transfected with MAP1S LC and the MH3 domain 
of MAP1B. MAP1S LC alone localised on microtubules, the MH3 domain of 
MAP1B alone was distributed in the nucleus and in the cytoplasm. In the 
presence of MAP1S LC, the MH3 domain of MAP1B was found to co-localise 
with MAP1S LC on microtubules, indicating that the MH3 domain of MAP1B 
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could bind to MAP1S LC and the two LCs could possibly form heterodimers 
(figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. MAP1S LC interacts with the MH3 domain of MAP1B LC. PtK2 cells were 
transfected with constructs encoding myc-tagged MAP1S LC (MAP1S LC-myc), HA-
tagged MH3 domain of MAP1B LC (MH3B-HA) or co-transfected with both constructs. 
After incubation for 48 hours to allow for protein expression, cells were fixed and 
analysed by triple immunofluorescence microscopy using antibodies against tubulin 
(anti-tubulin), the myc-tag (anti-myc) and the HA-tag (anti-HA). MAP1S LC was 
localised on microtubules, MH3B was diffusely distributed in the nucleus and in the 
cytoplasm. Nuclear localisation of MH3B was observed previously (Tögel, 1998) and is 
probably due to passive diffusion of this protein domain into the nucleus due to its small 
size. In the presence of MAP1S LC, MH3B was found to co-localise with MAP1S LC on 
microtubules (arrows). 
 
Blot overlay analysis using recombinant proteins was performed to confirm the 
interaction between MAP1S LC and MAP1B LC (figure 7). Immunoblotting with 
antibodies against MAP1B LC showed that recombinant MAP1B LC could 
interact with recombinant MAP1S LC fractionated on SDS-PAGE.    
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Figure 7. Interaction of MAP1S LC with MAP1B LC. 3-6µg (depending on the protein 
size to achieve equal molarity) of purified His-tagged recombinant MAP1S LC and BSA 
(negative control) were fractionated by SDS-PAGE. The gel was stained with 
Commassie to verify the protein content. Replica gels were blotted, probed with purified 
recombinant His-tagged MAP1B LC and immunodecorated with antibodies against 
MAP1B LC (anti-MAP1B LC). MAP1S LC, but not BSA, interacted with MAP1B LC.   
 
The potential S-nitrosylation of MAP1S and its influence on 
microtubule binding compared to other MAP1 proteins 
 
It was shown that MAP1B LC is S-nitrosylated on cys 2457 (Stroissnigg et al., 
2007). Sequence alignment of MAP1A LC, MAP1B LC and MAP1S LC revealed 
that all three LCs contain two cysteins and that the nitrosylated cystein of the 
MAP1B LC is conserved in all three LCs (figure 8).    
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MAP1A LC   madpeglssesgrverlre--kgrpgrrapg-rakpasparrl
MAP1B LC   mvdpealaieqnlgkalkkdlkekaktkkpgtktkssspvkkg
MAP1S LC   mvdpealpprarqplnttn--psr-srkapa-rpssasatpra
MAP1A LC   dirgk---rsptpg--kgpvdrtsr-----------------t
MAP1B LC   dgkskpsaaspkpgalkessdkvsrvaspkkkesvekamkttt
MAP1S LC   atvaa---ktkgpa---gdrnrpls-----------------a
MAP1A LC   vprprstpsqvtsaeekdghspmsk-glvnglkag----stal
MAP1B LC   tpevkatrgeekdketknaanasas-ksvktatagpgttktak
MAP1S LC   rsepadrpgrvpltrkpsvpktvpkmasatrlssg----psgr
MAP1A LC   gskggsgppvyvdlayipnhcsgktadqdffrrvrasyyvvsg
MAP1B LC   sstvppglpvyldlcyipnhsnsknvdveffkrvrssyyvvsg
MAP1S LC   paplaagspvyldlaylpgggagh-ldqnfflrvralcyvisg
MAP1A LC   ndpangepsravldallegkaqwgenlqvtlipthdtevtrew
MAP1B LC   ndpaaeepsravldallegkaqwgsnmqvtlipthdsevmrew
MAP1S LC   qgqrqeeglravldallagkrqwdldlqvtliptfdsavmhrw
MAP1A LC   yqqtheqqqqlnvlvlassstvvmqdesfpackief
MAP1B LC   yqethekqqdlnimvlassstvvmqdesfpackiel
MAP1S LC   yeethaqhqalgirvlgsgslvsmqdeafpackvef
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Sequence alignment of MAP1B, MAP1A and MAP1S LCs. Sequences of 
murine MAP1A LC, MAP1B LC and MAP1S LC were compared. Blue letters indicate 
amino acids conserved in all three proteins, orange letters amino acids conserved in 
MAP1A and MAP1B, green letters amino acids conserved in MAP1A and MAP1S and 
red letters amino acids conserved in MAP1B and MAP1S. All three MAP1 LC 
sequences contain two cysteins (in squares). The cystein at the C terminus (cys 2457 
in MAP1B, which can be nitrosylated) is conserved in its position and flanking 
sequences in all three LCs.  
 
One requirement for the S-nitrosylation is the close proximity of the nitric oxide 
producing enzyme nNOS and its target protein (Stamler et al., 1997). Evidence 
for the interaction of MAP1B LC with the PDZ domain of nNOS was obtained by 
yeast 2-hybrid β-galactosidase assay (Stroissnigg et al., 2007). To analyse the 
interaction between MAP1S LC and nNOS, blot overlay analysis with 
recombinant proteins was performed (figure 9). The interaction between MAP1B 
and the PDZ domain of nNOS could be confirmed and a weak interaction 
between MAP1S and nNOS was also found.    
  43
72kD
55kD
45kD
35kD
25kD
72kD
55kD
45kD
35kD
25kD
72kD
55kD
45kD
35kD
25kD
Commassie
anti-MAP1B LC
MAP1B LC +
anti-MAP1S LC
MAP1S LC +
PD
Z-
nN
OS
BS
A
PD
Z-
nN
OS
BS
A
BS
A
PD
Z-
nN
OS
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Interaction of MAP1B LC and MAP1S LC with the PDZ domain of nNOS. 
3-6µg (depending on the protein size to achieve equal molarity) protein purified His-
tagged recombinant PDZ-domain of nNOS (PDZ-nNOS) and BSA (as negative control) 
were fractionated by SDS-PAGE. The gel was stained with Commassie to verify the 
protein content. Replica gels were blotted, probed with recombinant His-tagged MAP1B 
LC or with recombinant MAP1S LC and immunodecorated with antibodies against 
MAP1B LC (anti-MAP1B LC) or MAP1S LC (anti-MAP1S LC), respectively. MAP1B LC 
interacted with the PDZ domain of nNOS (the upper band reflects the band detected 
with Commassie, the lower band shows the binding of MAP1B LC to a minor protein 
species perhaps representing a degradation product of PDZ-nNOS isolated from E.coli) 
and MAP1S LC interacted weakly with the PDZ domain of nNOS.  
 
Moreover, interaction and close proximity of MAP1B LC and nNOS was shown 
in co-transfected PtK2 cells. Whereas nNOS was found to be diffuse in 
cytoplasm when transiently transfected in PtK2 cells, it was found on 
microtubules co-localising when co-transfected with MAP1B LC. Likewise, the 
interaction between MAP1S LC and nNOS was analysed by co-transfecting 
PtK2 cells. PtK2 cells were co-transfected with MAP1S LC and the full length 
nNOS protein. In contrast to the results obtained with MAP1B LC, nNOS was 
still found diffusely distributed throughout the cytoplasm despite the presence of 
MAP1S LC on microtubules suggesting that nNOS and MAP1S do not interact 
in vivo (figure 10).  
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Figure 10. MAP1S LC was not found to bind to nNOS in vivo. PtK2 cells were 
transiently transfected with myc-tagged MAP1S light chain (MAP1S LC-myc), HA-
tagged nNOS (nNOS-HA) or co-transfected with both constructs. After incubation for 
48 hours to allow for protein expression, cells were fixed and analysed by triple 
immunofluorescence microscopy using antibodies against tubulin (anti-tubulin), the 
myc-tag (anti-myc) and the HA-tag (anti-HA). MAP1S LC was localised on 
microtubules, nNOS was diffusely distributed throughout the cytoplasm in the absence 
or presence of MAP1S LC. 
 
S-nitrosylation of MAP1B by treatment with the NO donor SNAP increased its 
microtubule binding activity (Stroissnigg et al., 2007). To analyse if the potential 
nitrosylation of MAP1A and MAP1S influences their microtubule binding activity, 
PtK2 cells were transiently transfected with MAP1A LC, MAP1B LC, or MAP1S 
LC and treated with SNAP or left untreated. While the binding of MAP1B LC to 
microtubules was significantly increased after SNAP treatment, no changes 
were observed in MAP1A or MAP1S expressing cells after SNAP treatment. In 
general, MAP1S LC was found more often on microtubules than MAP1B LC 
and MAP1A LC (figure 11).    
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Figure 11. Localisation of the LCs of MAP1B, MAP1A, and MAP1S on 
microtubules after treatment with the NO donor SNAP. PtK2 cells were transiently 
transfected with the myc-tagged LCs of MAP1B, MAP1A, or MAP1S. After incubation 
for 48 hours to allow for protein expression, cells were treated with 100µM SNAP for 4 
hours or left untreated and subsequently were fixed and analysed by double 
immunofluorescence microscopy using antibodies against tubulin (anti-tubulin) and the 
myc-tag (anti-myc). Cells were scored for localisation of the ectopically expressed 
protein in the cytoplasm or on microtubules. (A) Representative immunofluorescence 
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pictures were taken from transfected cells showing the expressed construct distributed 
diffusely in the cytoplasm (cytoplasmic) or binding (on MT/binding) to or binding to and 
bundling to microtubules (on MT/bundling). (B) Results from three independent 
experiments are presented as mean values, error bars representing standard 
deviations. Whereas the binding of MAP1B LC to microtubules was significantly 
increased after SNAP treatment (p=0.004, t-test), no changes were observed in 
MAP1A LC or MAP1S LC expressing cells. 
 
Next, PtK2 cells were transfected with constructs encoding full lenght proteins 
of MAP1B, MAP1S and a mutated, uncleavable form of MAP1B. The binding of 
MAP1B to microtubules was increased after SNAP treatment, confirming 
previous results (Stroissnigg, 2007). Binding of MAP1S or the uncleavable 
mutant of MAP1B to microtubules was not increased after SNAP treatment 
(figure 12). 
 
 
 
 
 
 
 
 
 
 
Figure 12. Binding of MAP1B FL, MAP1S FL, and an uncleavable MAP1B FL 
mutant to microtubules after treatment with the NO donor SNAP. PtK2 cells were 
transiently transfected with myc-tagged MAP1B FL, MAP1S FL or an uncleavable 
MAP1B FL mutant (lacking aa 2191-2221). After incubation for 48 hours to allow for 
protein expression, cells were treated with 100µM SNAP for 4 hours or left untreated, 
fixed, and analysed by double immunofluorescence microscopy using antibodies 
against tubulin and the myc-tag. Cells were scored for localisation of the ectopically 
expressed protein in the cytoplasma or on microtubules. Results from three 
independent experiments are presented as mean values, error bars representing 
standard deviations. A tendency of increased binding of MAP1B FL to microtubules 
was observed after SNAP treatment confirming previous results (Stroissnigg, 2007). 
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Binding of MAP1S FL or the uncleavable mutant of MAP1B FL to microtubules was not 
increased after SNAP treatment. 
 
When transiently overexpressed in PtK2 cells, MAP1S FL and MAP1S LC were 
found predominantly on microtubules (in 70-80%) of the cells. The appearances 
of microtubules decorated with MAP1S can either remain unchanged compared 
to non-transfected cells or changed to microtubule bundles (figure 11A). We 
were interested, whether SNAP can alter the ratio between MAP1S binding and 
bundling of microtubules. However, no differences were found after SNAP 
treatment. MAP1S LC was found more often to bundle microtubules compared 
to the MAP1S FL, independent of SNAP (figure 13).         
 
 
 
 
 
 
 
 
 
 
Figure 13. Binding to and bundling of microtubules by MAP1S after treatment 
with the NO donor SNAP. PtK2 cells were transiently transfected with myc-tagged 
MAP1S LC or MAP1S FL. After incubation for 48 hours to allow for protein expression, 
cells were treated with 100µM SNAP for 4 hours or left untreated, fixed and analysed 
by double immunofluorescence microscopy using antibodies against tubulin and the 
myc-tag. Cells were scored for localisation of the ectopically expressed protein in the 
cytoplasma, binding to, and bundling of microtubules. Results from three independent 
experiments are presented as mean values, error bars representing standard 
deviations. No effects of SNAP on microtubule binding and bundling of MAP1S LC or 
MAP1S FL were observed. 
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The influence of S-nitrosylation on the formation of an 
additional LC isoform  
 
In our laboratory, an additional MAP1B LC isoform was detected with an 
antibody against MAP1B LC as an additional band in immunoblotting analysis of 
protein lysates of brain under non-reducing conditions (unpublished data, Daniel 
Lackner). We were interested to investigate if LCs of MAP1A and MAP1S also 
form additional isoforms and if the formation of MAP1B isoforms is connected to 
its nitrosylation. I confirmed the detection of the additional MAP1B LC isoform in 
brain lysates and also detected it in lysates of neuroblastoma (N2a) cells. 
Results concerning MAP1A isoforms were not clear. Concerning MAP1S LC, 
only one band was found (figure 14). 
 
A 
 
 
 
B 
 
 
 
 
 
 
Figure 14. An additional MAP1B LC isoform was detected in immunoblotting 
analysis of protein lysates of brain and neuroblastoma (N2a) cells under non-
reducing conditions. (A) Whole mouse brain (adult) and N2a cells were homogenised 
in a non-reducing buffer (H). Aliquots of the lysates were treated with DTT (+DTT) or 
EtSH (+EtSH). 120µg of protein from these samples were analysed by SDS-PAGE and 
immunoblotting with an antibody against MAP1B LC (anti-MAP1B LC) or with 
secondary antibody only (no ab). The position of the MAP1B LC is indicated. Two 
bands were seen on blots of brain and N2a cell lysates under non-reducing condition. 
The lower band was not detected after adding DTT or EtSH.  (B) 120µg of protein (total 
lysate) from N2a cells, homogenised in a non-reducing buffer (H), were analysed by 
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SDS-PAGE and immunoblotting with antibodies against MAP1A LC (anti-MAP1A LC), 
MAP1B LC (anti-MAP1B LC) or MAP1S LC (anti-MAP1S LC). Results obtained with 
anti-MAP1A LC are not clear, as more, probably unspecific, bands were detectable. 
Two bands were detected with anti-MAP1B LC, but only one with anti-MAP1S LC.   
 
To analyse the role of nitrosylation of MAP1B LC in the formation of the 
additional band, N2a cells were transfected with constructs encoding myc-
tagged MAP1B LC or mutated MAP1B LCs, in which one of two cysteine 
residues was replaced with serine. Both cysteins were necessary for the 
appearance of the additional MAP1B LC band (figure 15A). In addition, after 
treatment with NPA, an nNOS inhibitor, only one band appeared (figure 15B). 
This suggests that the nitrosylation of MAP1B LC and the presence of the two 
cysteins were important for the formation of the additional MAP1B LC isoform. 
To test if this formation occurs in vivo, I treated N2a cells with NEM, which 
reacts with and blocks free S-H groups in the cells in vivo. Only one band 
appeared after treatment with NEM, indicating that the additional band of 
MAP1B LC is formed not in vivo, but during the homogenisation process (figure 
15C).   
 
A 
 
 
 
B 
 
 
 
C 
 
 
 
 
Figure 15. Both cysteins of MAP1B LC and the activity of nNOS were necessary 
to form an additional MAP1B LC isoform. (A) N2a cells were transfected with 
  50 
constructs encoding myc-tagged MAP1B LC, myc-tagged C2354S mutant or the myc-
tagged C2457S mutant. In these mutants the cystein on position 2354 or 2457 is 
replaced with serine. 120µg of protein (total lysate) were analysed by SDS-PAGE and 
immunoblotting with an antibody against myc (anti-myc). The position of the MAP1B LC 
is indicated. Two bands were observed on blots of lysates of cells transfected with 
constructs encoding MAP1B LC, only one after transfection with mutated MAP1B LCs. 
Both cysteins were necessary for the formation of the additional MAP1B LC band. (B) 
N2a cells were treated with 1mM of the nNOS inhibitor NPA for 1 hour and 
homogenised in a non-reducing buffer (H). Aliquots of the lysates were treated with 
DTT (+DTT) or EtSH (+EtSH). 120µg of protein from these samples were analysed by 
SDS-PAGE and immunoblotting with an antibody against MAP1B LC (anti-MAP1B LC). 
Only one band of MAP1B LC appeared after NPA treatment. The activity of nNOS was 
necessary for the formation of the additional MAP1B LC. (C) N2a cells were left 
untreated (untr.) or treated with 1mM or 5mM NEM (binds to S-H groups in the cells in 
vivo) for 15 minutes and homogenised in a non-reducing buffer (H). Aliquots of the 
lysates were treated with DTT (+DTT). 120µg of protein (total lysate) were analysed by 
SDS-PAGE and immunoblotting with an antibody against MAP1B LC (anti-MAP1B LC). 
Two bands were detected in untreated cell lysates. Only one band was visible after 
treatment with NEM, indicating that the additional band of MAP1B LC is formed not in 
vivo, but during the homogenisation process.   
 
Posttranslational cleavage of MAP1S 
 
All members of the MAP1 family are synthesised as precursor proteins and 
posttranslationally cleaved into HC and LC. Whereas MAP1A and MAP1B 
precursor proteins are hardly detected in protein extracts, MAP1S appears to be 
cleaved in a tissue specific pattern (Orban-Nemeth et al., 2005). I confirmed the 
cleavage pattern of MAP1S. Whereas MAP1S was completely cleaved in brain 
and testis cells, it was only partially cleaved in lung and nearly completely 
uncleaved in spleen (figure 16). Sequence alignment of murine MAP1A, MAP1B 
and MAP1S revealed that the cleavage site is highly conserved (figure 17).  
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Figure 16. Tissue specific cleavage pattern of MAP1S. 120µg of protein (total 
lysate) from the indicated mouse tissues (adult) were analysed by SDS-PAGE and 
immunoblotting with affinity-purified antibodies against MAP1S HC (anti-MAP1S HC) or 
LC (anti-MAP1S LC). Protein bands of 120kD correspond to the uncleaved MAP1S FL 
polyprotein precursor (MAP1S FL). Protein bands of 100kD and 26kD correspond to 
the HC and the LC of MAP1S, respectively. The MAP1S precursor was not detectable 
in brain and testis indicating that most or all of it was cleaved into a HC and a LC. In 
contrast, the FL precursor was only partially cleaved in lung and spleen. In lung and 
spleen, a band corresponding to the LC was not detected with anti-MAP1S LC, 
probably due to the comparatively lower level of expression of MAP1S in these tissues 
and the lack of complete cleavage of the FL MAP1S polyprotein precursor.    
 
 
 
 
 
 
 
 
Figure 17. MAP1 proteins including MAP1S are conserved around the 
presumptive cleavage site of the precursor protein. Alignment of murine MAP1A, 
MAP1B, MAP1S, and drosophila Futsch showed a highly conserved sequence at the 
presumptive cleavage site (Zou et al., 2008a). Blue letters indicate amino acids 
conserved in all three proteins, orange letters amino acids conserved in MAP1A and 
MAP1B, green letters amino acids conserved in MAP1A and MAP1S, and red letters 
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amino acids conserved in MAP1B and MAP1S. Pink letters indicate amino acids  
conserved in Futsch and any of the murine MAP1 protein.   
 
To investigate the cleavage of MAP1S, an appropriate cell culture system had 
to be found. Therefore, different cell lines were analysed by immunoblotting. 
N2a cells and NIH3T3 cells expressed partially cleaved MAP1S. In PtK2 cells 
no MAP1S was detected (figure 18).  
 
 
 
 
 
 
 
 
 
Figure 18. Cleavage pattern of MAP1S in different cell lines. 120µg of protein (total 
lysate) from adult mouse brain and the indicated cell lines were analysed by SDS-
PAGE and immunoblotting with antibodies against MAP1S HC (anti-MAP1S HC) or LC 
(anti-MAP1S LC). Protein bands of 120kD correspond to the MAP1S FL. Protein bands 
of 100kD and 26kD correspond to the HC and the LC of MAP1S, respectively. MAP1S 
was expressed and partially cleaved in neuroblastoma N2a cells and NIH3T3 
fibroblasts. MAP1S was not detected in PtK2 cells, perhaps due to the lack of 
crossreactivity of the anti-mouse MAP1S antibodies used here with potoroo MAP1S 
(PtK2 cells).   
 
N2a cells, derived from murine neuroblastoma, were chosen to examine the 
length of time between the synthesis of MAP1S, its cleavage and its 
degradation. One method to measure the protein metabolism is to label proteins 
with 35S methionine/cysteine as described under materials and methods. Due to 
difficulties with the immunoprecipitation of radioactively labelled cells, the small 
amount of protein and inconsistent results, a faster and easier method was 
used to examine cleavage time and time for degradation. N2a cells were treated 
with the protein translation suppressor cycloheximide for one to six hours and 
MAP1S proteins were analysed by immunoblotting. No differences in the 
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cleavage pattern were found, indicating that the MAP1S precursor as well as 
the HC were stable proteins with comparatively slow turnover (figure 19).   
 
 
 
 
 
 
Figure 19. Cleavage pattern of endogenous MAP1S in N2a cells after treatment 
with the protein synthesis inhibitor cycloheximide. 120µg of protein (total lysate) 
from N2a cells treated with 100µg/ml cycloheximide (Cyc.) for 1, 3 or 6 hours or left 
untreated (untr.) were analysed by SDS-PAGE and immunoblotting with an antibody 
against MAP1S HC (anti-MAP1S HC). The positions of the MAP1S FL and the MAP1S 
HC are indicated. The protein level of MAP1S stayed constant over the tested period. 
No difference in the cleavage pattern was found, indicating that the MAP1S precursor 
as well as the HC were stable proteins with comparatively slow turnover.  
 
The influence of S-nitrosylation on the posttranslational 
cleavage of MAP1S 
 
To analyse the potential influence of S-nitrosylation of MAP1S on the cleavage 
pattern of MAP1S, N2a cells were treated with the nNOS inhibitor NPA. Cell 
lysates were analysed by immunoblotting. Treatment with NPA had no influence 
on the cleavage pattern of endogenous or ectopically expressed MAP1S (figure 
20).  
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Figure 20. N-ω-propyl-L-arginine (NPA) did not influence the cleavage pattern of 
MAP1S. (A) N2a cells were transiently transfected with COOH-terminally myc-tagged 
MAP1S FL and treated with 1mM NPA in serumfree medium for 10 minutes, 30 
minutes, 1 hour or 3 hours or left untreated (untr.). 120µg of protein (total lysate) from 
these cells were analysed by SDS-PAGE and immunoblotting with an antibody against 
myc (anti-myc). The positions of the myc-tagged MAP1S uncleaved precursor protein 
(MAP1S FL) and the MAP1S LC are indicated. (B) 120µg of protein (total lysate) from 
untransfected N2a cells grown in growth medium containing serum (C) or treated with 
1mM NPA or without NPA (untr.) in serumfree medium for 1 or 24 hours were analysed 
by SDS-PAGE and immunoblotting with antibodies against MAP1S HC (anti-MAP1S 
HC). The positions of the MAP1S FL and the MAP1S HC were indicated. Treatment 
with NPA for 10 minutes showed decreased level of MAP1S FL, but this effect was not 
consistently observed in a repeated experiment (data not shown). Therefore we 
conclude that NPA had no influence on the cleavage pattern of the ectopically and 
endogenously expressed MAP1S.  
 
N-ε-acetylation of MAP1 proteins 
 
To analyse the potential N-ε-acetylation of MAP1 proteins on lysine residues, 
microtubule proteins were purified from wild-type and MAP1B knockout mouse 
brains and analysed by immunoblotting. The antibody against N-ε-acetylated 
lysine showed that MAP1B LC was acetylated. MAP1S was not detected and 
therefore appeared to be not acetylated (figure21).   
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Figure 21. MAP1B LC was acetylated. Purified microtubule proteins from brains from 
one to four day old C57BL/6J (wt) or MAP1B knockout (1Bko) mice were analysed by 
SDS-PAGE and immunoblotting. Acetylated BSA was used as a positive control. (A) 
Blots were stained with amidoblack to verify protein content on the blot. (B) The same 
blots were then immunodecorated with antibodies against MAP1B LC (anti-MAP1B 
LC), N-ε-acetylated lysine (anti-Acet.), MAP1S HC (anti-MAP1S HC) and MAP1S LC 
(anti-MAP1S LC). Positions of MAP1S HC, MAP1S LC and MAP1B LC are indicated. 
Dashed lines indicate original protein lanes, solid lines show where the blot was cut for 
the incubation with indicated antibodies. The antibody against N-ε-acetylated lysine 
showed that MAP1B LC was acetylated. It remains unclear why the antibody against N-
ε-acetylated lysine did not detect tubulin, which was expected to be acetylated.  
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DISCUSSION 
 
Homotypic and heterotypic complexes of MAP1 proteins 
 
Homotypic complexes, consisting of MAP1B HC-MAP1B LC, MAP1A HC-
MAP1A LC, or MAP1S HC-LC, and the heterotypic complex consisting of 
MAP1A HC-MAP1B LC were found in co-immunoprecipitation analysis 
(Kuznetsov et al., 1986; Langkopf et al., 1992; Noiges et al., 2006; Orban-
Nemeth et al., 2005; Schoenfeld et al., 1989). I found the heterotypic complex 
MAP1B HC-MAP1A LC in mouse brain at certain times in development, when 
both proteins are co-expressed. These heterotypic complexes may play an 
important role in the function of MAP1A and MAP1B, especially during brain 
development. The capacity to form homotypic as well as heterotypic complexes 
may provide neurons the opportunity to subtly regulate the formation of 
microtubules and actin filaments during the critical transition period, when 
neurons shift from axon extension to axon stabilisation and synaptogenesis 
(Noiges et al., 2002; Tögel et al., 1998). Due to results from blot overlay and 
yeast 2-hybrid β-galactosidase assays, we assumed that the homotypic as well 
as heterotypic complexes are formed through direct interaction between the 
MH1 domain of HCs and the MH3 domain of LCs (Noiges et al., 2006). As 
these domains are conserved between all three MAP1 proteins, MAP1S might 
also form heterotypic complexes. I could show in co-transfection experiments 
that the MAP1S LC can also form heterotypic complexes via MH1 and MH3 
domains of MAP1B. Furthermore the interaction between MAP1S LC and 
MAP1B LC was shown in overlay blot assay with recombinant proteins.  
Previous studies identified MAP1A as well as MAP1B complexes consisting of 
one HC and two LCs (Mei et al., 2000; Schoenfeld et al., 1989). To form such 
complexes, two LCs form probably homo- or heterodimers and bind as such to 
a single site in the HC (Noiges et al., 2006). Our results indicate that the 
MAP1S LC can integrate in these complex formations. On the one hand MAP1S 
LC could bind directly to the MAP1B HC, on the other hand MAP1S LC could 
bind indirectly to the MAP1B HC via forming a heterodimer with the MAP1B LC. 
Due to the conserved domains in MAP1A, MAP1S may also take part in the 
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formation of MAP1A complexes in the same way. While MAP1A is expressed at 
low levels at birth and then increases over the next three weeks and MAP1B is 
expressed at high levels at birth and then decreases, MAP1S is expressed at a 
high level at birth and remains at high levels in adulthood (Orban-Nemeth et al., 
2005; Schoenfeld and Obar, 1994). Thus MAP1S is co-expressed with MAP1A 
or MAP1B at all times in brain development and putative heterotypic complexes 
may have specific individual properties, which are essential for the proper 
development and function of the murine brain.   
 
The potential S-nitrosylation of MAP1S and its influence on 
microtubule binding compared to other MAP1 proteins 
 
The S-nitrosylation of the MAP1B LC was demonstrated in vivo, in cultured cells 
and in vitro. This nitrosylation of MAP1B LC leads to enhanced binding to 
microtubules and causes neurite retraction (Stroissnigg et al., 2007). We were 
interested to see whether the MAP1S LC is also S-nitrosylated. Sequence 
alignment illustrates that the nitrosylated cystein of the MAP1B LC (cystein 
2457) is conserved in the MAP1A LC and MAP1S LC. As S-nitrosylation is a 
covalent modification of cystein residues achieved through a non-catalysed 
chemical modification, it is not enzyme driven as for example phosphorylation. 
Therefore the reaction specifity does not rely on the recognition of a target 
structure by an enzyme (Martinez-Ruiz and Lamas, 2004). Nevertheless, due to 
the strong reactivity of the NO· radical the close proximity of the oxid producing 
enzyme nNOS and its target protein is one of the requirements for S-
nitrosylation (Martinez-Ruiz and Lamas, 2004; Stamler et al., 1997). In blot 
overlay assays, an interaction of the PDZ domain of nNOS and the MAP1S LC 
was seen, but this interaction was relatively weak compared to the interaction 
with MAP1B LC. In co-transfected PtK2 cells, no interaction between MAP1S 
LC and nNOS was found. Immunofluorescence analysis had revealed that the 
MAP1B LC interacts not only with the PDZ domain of nNOS, but there exist 
probably additional interaction sites, because the MAP1B LC was also co-
localising with an nNOS mutant lacking the PDZ domain (Trančiková, 2007; 
Trančiková, PhD thesis 2007). These data suggest that, although the MAP1S 
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LC binds to the PDZ domain of nNOS in vitro, this binding is not efficient for the 
interaction of the MAP1S LC with the nNOS protein in vivo. MAP1S LC probably 
misses additional interaction sites, which might be necessary for the binding to 
nNOS in vivo. To clarify whether MAP1S LC is nitrosylated or not, more 
experiments would have to be done. Several methods are known to detect 
individual S-nitrosylated proteins. So date, the “biotin switch” method, in which 
the cystein-bound NO is replaced by a biotin label, in combination with 
immunoblot to confirm modification of individual proteins would be the most 
adequate method to verify the S-nitrosylation of MAP1S LC (Jaffrey and 
Snyder, 2001; Martinez-Ruiz and Lamas, 2004).   
The S-nitrosylation of MAP1B LC does not alter its interaction with actin 
(Stroissnigg, PhD thesis 2005), but leads to increased microtubule binding 
(Stroissnigg et al., 2007). When PtK2 were transfected to transiently 
overexpress MAP1B FL or LC, treatment with the NO donor SNAP increased 
the microtubule binding activity of MAP1B (Stroissnigg et al., 2007; Trančiková, 
PhD thesis 2007). To compare the effect of the NO donor SNAP on the 
microtubule binding of MAP1A, MAP1B, and MAP1S, PtK2 cells were 
transfected with constructs encoding MAP1A LC, MAP1B LC, MAP1S LC, 
MAP1B FL, MAP1S FL and an uncleavable mutant of MAP1B FL. Beside 
confirming the increase of the microtubule binding activity of MAP1B FL and LC, 
no other alterations were found after SNAP treatment. As both, MAP1S FL and 
MAP1S LC, were found predominantly on microtubules (70-80%), I speculated 
that the effect of the SNAP treatment might be masked and looked for changes 
in the ratio between MAP1S binding and bundling of microtubules. I could find 
no alteration after SNAP treatment in the ratio between MAP1S binding and 
bundling of microtubules. According to our results one might speculate that 
MAP1S and MAP1A are not modified by S-nitrosylation, but we can not exclude 
it. If MAP1S and MAP1A LCs were to be nitrosylated, their nitrosylation would 
not affect their microtubule binding activity. Definitely, one can conclude that the 
regulation of the microtubule binding activity by S-nitrosylation is a unique and 
specific attribute of MAP1B LC among the members of the MAP1 family. Two 
recent reports indicated that MAP1B and MAP1S interfere with dynein motor 
activity and can block dynein-dependent retrograde transport (Ding et al., 
2006a; Jimenez-Mateos et al., 2006). Stroissnigg et al. propose that the 
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increased binding of the MAP1B HC-LC complex to microtubules, due to S-
nitrosylation of the MAP1B LC, might inhibit dynein action and lead to a 
reduction of the extension force, resulting in axon retraction (Stroissnigg et al., 
2007). My findings suggest that MAP1S does not act via the same mechanism. 
Intererstingly, the ability of the different LCs to bind to microtubules varies (34% 
of MAP1A LC, 67% of MAP1B LC, 81% of MAP1S LC expressing cells) in 
untreated cells. In contrast to MAP1B FL, ectopically expressed MAP1S FL 
binds very well to microtubules (Orban-Nemeth et al., 2005). Ding et al. showed 
that overexpressing MAP1S impaired the retrograde axonal transport in DRGs 
lacking GAN (Ding et al., 2006a).  One can speculate that the binding of the 
unmodified MAP1S LC to microtubules is sufficient enough to impair this 
retrograde axonal transport. 
Previous studies in our laboratory suggest that both, the proteolytic processing 
of MAP1B and the presence of the MH1 domain are essential for its microtubule 
binding, whereas the MH2 domain has an inhibitory effect. Several constructs 
were used to obtain these results, but a mutant lacking only the cleavage site 
was never tested (Trančiková, PhD thesis 2007). Here I analysed the binding 
ability of a mutant MAP1B FL lacking only 31 amino acid residues (in rat 
MAP1B 2193-2223) including and flanking the cleavage site presumably at 
amino acid 2204 of MAP1B (Tögel et al., 1999; Zou et al., 2008a). Suprisingly, 
comparing the results of MAP1B FL (11% of cells showed microtubule binding) 
to the mutant MAP1B FL (18% of cells showed microtubule binding), no 
significant difference in the microtubule binding ability was found. According to 
these results, we could clarify that the proteolytic processing of MAP1B is not 
essential for its microtubule binding. Concerning the previous studies in our 
laboratory by Trančiková (Trančiková, PhD thesis 2007), the influence of MH1 
and MH2 seems to be crucial for the microtubule binding ability of MAP1B.  
 
The influence of S-nitrosylation on the formation of an 
additional LC isoform  
 
Previous results from our laboratory showed an additional MAP1B LC band 
detected with an antibody against MAP1B LC in immunoblot analysis of protein 
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lysates of brain under non-reducing conditions (unpublished data, Daniel 
Lackner). I could show that this additional MAP1B LC isoform was present in 
protein lysates of brain and neuroblastoma (N2a) cells under non-reducing 
conditions. Concerning MAP1S, only one isoform was detectable. According to 
these results, the nitrosylation of MAP1B LC and the presence of the two 
cysteins are important for the formation of the second MAP1B LC isoform. To 
test if this isoforms occur in living cells before homogenisation or are perhaps a 
product of MAP1B LC oxidation during cell lysis, cells were treated with NEM, 
which binds to free S-H groups in the cells in vivo. Only one isoforms was 
detectable after treatment with NEM prior to cell lysis, indicating that the 
additional isoform of MAP1B LC is not present in live cells, but is generated 
during the homogenisation process. According to these data, I propose a model 
for the formation of the additional MAP1B LC isoform. The additional band 
might represent a more compact isoform of the MAP1B LC, which is formed via 
a disulfide bridge between the two cysteins (C-S-S-C) during the 
homogenisation process and migrates faster on the gel (figure 22).    
 
 
 
    
 
 
 
 
 
 
Figure 22. A model for the formation of the faster migrating MAP1B LC isoform. 
The additional MAP1B LC band detected on blots of polyacrylamid gels run under non-
reducing conditions probably represents a more compact isoform of MAP1B LC formed 
via a disulfide bridge between the two cysteins (C-S-S-C). This putative isoform of the 
MAP1B LC was only observed with the wild-type MAP1B LC where both cysteins are 
present, and when nNOS was active. If only one cystein was present, like in the 
MAP1B LC mutants, no bridge would be formed. After NPA treatment of the cells the 
additional isoform was not detectable. Thus, it is conceivable that oxidation of the 
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nitrosylated form of MAP1B LC by oxygen during homogenisation leads to formation of 
a disulphide bridge and a more compact isoform of MAP1B LC. NEM treatment of cells 
prior to homogenisation prevented the formation of this compact isoform, indicating that 
it was formed during the homogenisation process. NEM covalently modifies free S-H 
groups, preventing the subsequent oxidation and formation of disulfide bridges. If the 
compact isoform of MAP1B LC would already exist in vivo, NEM treatment just before 
homogenisation would not affect the existing disulfide bridges (C-S-S-C) and the faster 
migrating isoform should still be detectable after NEM treatment.        
 
The influence of nNOS activity on posttranslational cleavage of 
MAP1S  
 
All members of the MAP1 family are synthesised as precursor proteins that are 
posttranslationally cleaved into HCs and LCs. Generally, protein precursors are 
seen as inactive proteins and their proteolytic cleavage represents an 
irreversible activation or maturation into an activ form. It is conceivable that 
protein precursors act as a reservoir of inactive isoforms that can be activated 
on short notice and/or in large quantities. Sequence alignment revealed that the 
cleavage site is highly conserved in all members of the MAP1 family. The exact 
cleavage site was determined and the strong sequence conservation suggests 
a conserved cleavage mechanism (Zou et al., 2008a). However, no candidate 
mechanism or protease has been identified up to now. Whereas MAP1A and 
MAP1B precursor proteins are hardly detected in protein extracts, MAP1S is 
only partially cleaved in a tissue specific pattern (Orban-Nemeth et al., 2005). 
Interestingly, in brain, where MAP1B and MAP1A are predominantly expressed, 
MAP1S is found to be cleaved completely. One possibility is that all three MAP1 
proteins are cleaved by the same cleavage mechanism and that this 
mechanism is differentially active in in certain tissues. The limitation of the 
cleavage mechanism might be due to distinct availability of the protease.  
In was proposed that the MAP1B HC acts as a regulatory subunit to control the 
activity of the MAP1B LC (Tögel et al., 1998). Also the MAP1S HC seems to 
regulate the activity of MAP1S LC, because when the MAP1S LC is expressed 
together with the HC, microtubule bundling and stabilisation are absent (Orban-
Nemeth et al., 2005). Treatment with the protein translation suppressor 
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cycloheximide revealed that the MAP1S FL as well as the MAP1S HC are 
stable over 6 hours. Moreover, Ding et al. reported that even eight hours after 
cycloheximide addition, the majority of the MAP1S LC still remains (Ding et al., 
2006a). These results indicate that the precursor protein as well as the cleaved 
MAP1S are relatively stable proteins with comparatively slow turnover and that 
the precursor MAP1S may act as long time storage. Neverthless, the question 
remains, why the amount of cleaved versus uncleaved MAP1S varies in a 
tissue specific manner. On the one hand the active, cleaved MAP1S may be 
potentially harmful in some tissues, but under specific conditions active MAP1S 
is needed. On the other hand the precursor protein itself may perform a 
biological function.  
So far, the mechanism of regulation of the cleavage of MAP1S has not been 
investigated. We found no influence of NPA on the cleavage of MAP1S, 
indicating that the inhibition of nNOS and therefore the inhibition of the potential 
S-nitrosylation of MAP1S does not influence the cleavage pattern of MAP1S.  
 
N-ε-acetylation of MAP1 proteins 
 
Acetylation occurs as a co-translational and posttranslational modification of 
proteins, for example, histones, p53, and tubulins. Beside N-α-terminal 
acetylation, posttranslational ε-amino lysine acetylation is emerging as a 
significant posttranslational regulatory mechanism of cytoskeletal proteins 
(Glozak et al., 2005). We purified MAPs from murine brain and analysed these 
proteins for their potential N-ε-acetylated lysine residues by using specific 
antibodies (Iwabata et al., 2005). We found only the MAP1B LC to be N-ε-
acetylated. MAP1S LC and HC did not react with the antibody against N-ε-
acetylated lysine indicating that they are not N-acetylated. Concerning MAP1A 
this question was not resolved as MAP1A is not expressed at high level in brain 
of mice of young age.  
Lysine residues are targets for both acetylation and ubiquitination. It is 
proposed, that acetylation status regulates protein stability, because one of 
these modifications seems to prevent the other (Glozak et al., 2005). Therefore, 
the acetylation of MAP1B LC might enhance its stability. Furthermore, the 
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acetylation of a protein can potentially modify its activity and might crosstalk 
with other posttranslational modifications (Yang and Seto, 2008). Interestingly, 
microtubules in cells transfected with MAP1B were observed to be more stable 
and were found to be enriched in acetylated tubulin (Takemura et al., 1992).  
Our finding of the acetylation of MAP1B LC provides an opportunity to 
investigate the mechanism of acetylation and stabilisation of tubulin by MAP1B 
LC.   
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PART II – 
GENERATION AND FIRST ANALYSIS OF 
MAP1S KNOCKOUT MICE 
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RESULTS 
 
The second and main part of this thesis deals with the generation and first 
analysis of a MAP1S deficient mouse line to gain insight into the function of 
MAP1S. After giving an overview of the knockout strategy and the generation of 
this new mouse line, the first analysis of its phenotype will be described.  
 
The conditional knockout strategy 
 
MAP1S is expressed in many mouse tissues and development stages (Orban-
Nemeth et al., 2005) and seems to play a role in mitosis (Dallol et al., 2007; 
Song et al., 2005). To circumvent the potential early lethality of MAP1S deletion, 
we decided to generate a conditional knockout mouse instead of a conventional 
knockout mouse. 
Strategies for conditional gene targeting in mice are based on the cre/loxP or 
flp/frt recombination system. In principle, the target gene is modified by 
homologous recombination in embryonic stem (ES) cells so that it is flanked by 
loxP sites orientated in the same direction. Mice carrying this mutation are then 
crossed with mice expressing cre in the desired target cell type to delete the 
gene only in these cells. The flp/frt recombination system operates the same 
way with an frt-site specific flp recombinase (Dymecki, 1996; Lewandoski, 2001; 
Sauer, 1998). An outline of the MAP1S conditional targeting strategy is given in 
figure 23. First, a targeting vector containing two loxP sites and an frt-flanked 
neomycin resistance gene was constructed (figure 25). Then ES cells were 
electroporated with the targeting vector to modify the MAP1S gene (wild-type) 
by homologous recombination. Successfully targeted ES cell clones were then 
used to generate mice with a targeted MAP1S gene also designated as being 
floxed. Next, the neomycin-resistance gene can be removed by the flp 
recombinase. This can be done by crossing mice with transgenic mice 
ubiquitously expressing flp recombinase (flp deleter mice). The gene expression 
of the floxed MAP1S gene should not be affected, since the first loxP site is 
integrated in an intron sequence and the second loxP site is integrated 
downstream of the exons of MAP1S. To cause gene ablation, this mouse line 
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can be crossed with another mouse line containing a cre transgene, expression 
of which is controlled by a defined promoter. In their offspring, recombination 
between the loxP sites will take place resulting in the deletion of the region 
flanked by the loxP sites. 
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Figure 23. Schematic representation of the strategy to generate conditional 
MAP1S knockout mice. (A) The genomic locus of MAP1S in wild-type mice consists 
of 7 exons (I-VII) on chromosome 8. (B) After targeting this locus with the targeting 
construct (figure 25) in ES cells, the MAP1S locus will contain two loxP sites (light grey 
rectangle) flanking exon II to VII and a neomycin-resistance (neo) gene flanked by frt 
sites (dark grey rectangle). The neomycin-resistance is needed for the selection of the 
ES clones. (C) First, mice with the targeted allele will be crossed to an flp expressing 
mouse strain to remove the neomycin-resistance gene and to generate a MAP1S allele 
that should function in a way indistinguishable from the wild-type allele except that it is 
susceptible to deletion of exon II to VII upon expression of cre recombinase. (D) To 
ablate exon II to VII, the cre recombinase will mediate the recombination between the 
two loxP sites.  
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The conditional knockout mice will have a mixed background, as the targeting 
vector will consist of DNA from the C57BL/6 strain, and ES cells will contain 
DNA from the 129 strain additionally. To elucidate differences in the MAP1S 
expression levels in the C57BL/6 and 129 mice, immunoblot analysis was 
performed (figure 24). MAP1S was found to be expressed in the same pattern 
and intensity in both mouse strains.  
 
 
 
 
 
 
Figure 24. MAP1S expression in mouse tissues of strains C57BL/6J and 129. 
100µg of protein (total lysate) from the indicated mouse tissues (adult) from C57BL/6 
(B6) or 129 were analysed by SDS-PAGE and immunoblotting with antibodies against 
the MAP1S heavy chain (anti-MAP1S HC). Protein bands of 120kD correspond to the 
uncleaved MAP1S FL. Protein bands of 100kD correspond to the heavy chain (HC). 
MAP1S was expressed in both mouse strains in the same pattern and intensity.  
 
Generation of conditional MAP1S knockout mice 
 
For the generation of the conditional MAP1S knockout mouse line several steps 
were necessary. First, a targeting vector was constructed. This vector contains 
exon II to exon VII of the MAP1S gene, flanked by two loxP sites, and a 
neomycin resistance gene, flanked by two frt sites (figure 25A). The cloning 
strategy is described in detail in Materials and Methods.  
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Figure 25. Targeting the MAP1S locus. (A) Schematic representation of the targeting 
construct (targeting vector), the MAP1S genomic locus (wild-type), and targeted allele 
(floxed neo) after homologous recombination (crosses). Exons (black boxes), 
restriction sites, and positions of external probes (grey boxes) are indicated. The 
targeting construct comprised a 13221bp XhoI fragment of genomic mouse DNA (strain 
C57BL/6, obtained from BAC RPCI-23_374C22) containing exon II to VII of the MAP1S 
gene plus flanking sequences. This fragment was modified through insertion (dashed 
lines) of an NsiI fragment, which was synthesised by PCR and contained exon II, exon 
III and one loxP site upstream of exon II. Additionally, a second loxP site and a 
neomycin-resistance gene flanked by frt sites were inserted (dashed lines) at an EcoRI 
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site downstream of exon VII. Through homologous recombination, the targeted 
construct was inserted in the genomic locus. To analyse the 5’ side of the targeted 
locus, genomic DNA was digested with HindIII or NheI to detect with the 5’ probe a 
23.7kb or 9.4kb fragment from wild-type, respectively and an 8.2kb or 7.8kb fragment 
from the floxed neo allele. To analyse the 3’ side of the targeted locus, genomic DNA 
was digested with HindIII or NheI to detect with the 3’ probe a 23.7kb or 7.8kb fragment 
from wild-type, respectively and an 8.4kb or 5.9kb from the mutated allele. (B) 
Southern blot analysis (autoradiography) was performed of genomic DNA prepared 
from an ES cell clone with an unaltered MAP1S locus (wt) and from successfully 
targeted clones (186 and 193) using 5’ probe or 3’ probe.  
 
Prior to electroporation into A9 ES cells (kindly provided by A. Meixner, IMP), 
the targeting vector was linearised. A9 ES cells are C57BL/6 and 129 hybrids 
and have an X/Y genotype. These ES cells were transfected by electroporation, 
neomycin (G418) resistant clones were picked, and genomic DNA was 
prepared and analysed for the type of recombination event by Southern blot 
analysis (figure 25). The Southern blot strategy had been tested before on DNA 
from C57BL/6 and 129 mice (data not shown). DNA from both mouse strains 
gave the same fragments (wild-type). To demonstrate the correct insertion of 
the targeting construct, two probes (5` and 3`) external to the targeting construct 
were used for hybridisation. From 276 analysed clones, three obtained the 
desired targeted MAP1S allele. Cells from one positive ES cell clone, number 
186, were then injected into blastocyts of C57BL/6 mice and blastocyts were 
transferred into foster mice (kindly done by C. Theussl and J. Wojciechowski). 
From three foster mice, seven male chimeras were obtained. Chimeric mice 
were then breed with C57BL/6 mice for back crossing. Some chimeric mice 
were crossed directly with cre deleter mice, transgenic mice ubiquitously 
expressing cre recombinase to generate mice carrying the ko neo allele in the 
germline. All chimera were fertile and transfered the targeted MAP1S allele to 
their offspring. Around 50% (41 out of 88) of the pups inherited the targeted 
allele. Southern blot analysis using external probes confirmed their genotype. 
Additionally, southern blot analysis using an internal probe, that hybridises with 
the neomycin resistance gene (neo probe), was performed (figure 26). This 
southern blot analysis, performed on DNA from offspring from chimeras mated 
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with either C57BL/6 or cre deleter mice, showed the predicted 7.5kb or 6.0kb 
Bgl II-fragment in diagnostic for the floxed neo and ko neo alleles, respectively. 
Surprisingly, a second band was detected with the neo probe.  
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Figure 26. Southern blot analysis using the neo probe revealed an additional 
band, which dissapeared after back crossing. (A) Schematic representation of the 
floxed neo allele and the knockout allele. Exons (black boxes), restriction sites, and the 
position of the internal neo probe (grey box) are indicated. To analyse the integration of 
the targeting vector, the genomic DNA was digested with Bgl II to detect with the neo 
probe a 7.5kb or a 6.0kb fragment from the floxed neo or the knockout neo allele, 
respectively. (B) Southern blot analysis (autoradiography) was performed of genomic 
DNA prepared from heterozygous floxed (fl) neo, from heterozygous knockout (ko) neo 
mice derived from 186 ES cell clone, and from 186 and 193 ES cell clones using the 
neo probe. In addition to the expected 7.5kb and 6.0kb Bgl II-fragments diagnostic for 
floxed neo and ko neo mice, respectively, a second band appeared (2 neo). This 
additional band disappeared after back crossing (1 neo) in both genotypes. ES clone 
(ES) number 186 showed two neo bands, ES clone 193 showed one neo band.  
 
The neomycin resistance does not exist in the wild-type genome (no band 
detected, data not shown), but in the targeting vector. Therefore we suspected 
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that the targeting vector, or at least a fragment containing the neomycin 
resistance gene, integrated not only in the MAP1S genomic locus, but also by 
non-homologous recombination at a second site. If this second integration took 
place on another chromosome or at sufficient distance from the MAP1S locus 
on chromosome 8, it whould be possible to obtain mice with only one integrated 
vector through backcrossing. Indeed, after three generations of backcrossing, 
mice showing just the expected band in southern blot analysis with the neo 
probe were obtained. 
Additionally, southern blot analysis of DNA from ES clones was performed. The 
ES clone number 186 showed two bands after hybridisation with the neo probe. 
Another positive ES cell clone, which contained the desired targeted MAP1S 
allele, showed only one band. This clone, number 193, was then injected into 
blastocyts of C57BL/6 mice and blastocyts were transferred into foster mice 
(kindly done by C. Theussl and J. Wojciechowski). From two foster mice, one 
female and five male chimeras were obtained. All of them were fertile and 
transfered the targeted MAP1S locus to their offspring.  
To facilitate and accelerate genotyping of mice, a PCR strategy was designed 
and established (figure 27). PCR analysis was performed on murine genomic 
DNA, isolated from tail tips. Five different primers were designed, named PG 
(Primer for Genotyping) 1 to 5. Three different PCRs were used to distinguish 
five different alleles. As all primers bind inside the region of the targeting vector, 
genotyping by PCR was only used once the correct targeting of the MAP1S 
locus was established by southern blotting.     
Mice heterozygous for the ko neo allele (obtained by breeding chimeras with cre 
deleter transgenics) were not distinguishable from their wild-type littermates. 
Heterozygous animals were then intercrossed to obtain mice homozygous for 
the ko neo allele.   
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Figure 27. PCR strategy to identify targeted MAP1S alleles. (A) Schematic 
representation of the wild-type genomic locus (wt), the floxed neo (fl neo), the floxed 
delta (fl Δ), the knockout neo (ko neo) and the knockout delta (ko Δ) allele. (B) Table of 
PCR products amplified with the appropriate primers to identify the indicated genotype. 
(C) PCR products obtained from DNA of a chimera (ch, line 186), a wt mouse, a 
heterozygous (het) fl neo, and a het ko neo were analysed on 1.8% agarose gels. 
Primers used to perform the PCR are indicated. (D) PCR products were analysed on a 
0.8% agarose gel. 
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General examination of homozygous knockout mice 
 
Intercrossing of heterozygous knockout neo mice revealed that homozygous 
knockout mice were viable. They were obtained at approximatly Mendelian ratio 
(Table 1). Their littersize with an average of 6.89 ± 2.6 pups was equal to the 
littersize of C57BL/6 mice (6-8 pups). Homozygous knockout neo mice showed 
no apparent phenotype compared to their wild-type littermates. They were 
viable and fertile.  
 
 
Number of progeny 
wild-type het knockout neo hom knockout neo 
 
n % n % n % 
Total born 28 34 38 46 16 20 
Adult male 9  19  8  
Adult female 19  19  8  
Postnatal lethality 0 0 0 0 0 0 
 
Table 1. Breeding statistics of MAP1S knockout mice. Heterozygous MAP1S 
knockout neo mice were paired and their offspring were genotyped at the age of three 
weeks. From 82 offspring, 34% (28) were wild-type, 46% (38) heterozygous (het) 
knockout neo, and 20% (16) homozygous (hom) knockout neo mice. No postnatal 
lethality after weaning was found.      
 
All of the following analyses were carried out using mice derived from ES clone 
186 and homozygous for the MAP1S ko neo allele and their wild-type 
littermates as controls. Hence, mice homozygous for the ko neo allele will be 
refered to as MAP1S knockout or MAP1S deficient mice. To confirm that the 
knockout neo allele is a null allele no longer encoding MAP1S, immunoblot 
analysis was performed of brain, lung, testis, spleen and liver from MAP1S 
knockout mice and their wild-type littermates (figure 28). No MAP1S expression 
could be detected in tissues from MAP1S knockout mice. As the antibody 
against the MAP1S heavy chain binds to the C terminus of the heavy chain, the 
expression of an N-terminal MAP1S fragment potentially encoded by exon I, 
which remain intact in the targeted allele, could not be analysed. The potentially 
encoded N-terminal MAP1S fragment would be 41 amino acids long. 
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Figure 28. Immunoblot analysis of the expression of MAP1S in wild-type and 
MAP1S knockout mice. 80 µg of protein (total lysate) extracted from the indicated 
mouse tissues (adult) from wild-type (wt) and MAP1S knockout (ko) mice were 
analysed by SDS-PAGE and immunoblotting with antibodies against MAP1S heavy 
chain (anti-MAP1S HC). Protein bands of 120kD correspond to the uncleaved full-
length MAP1S polyprotein precurser (MAP1S FL). Protein bands of 100kD correspond 
to the heavy chain (HC). MAP1S was expressed in wild-type, but not in MAP1S 
knockout mice.  
 
Histological analysis  
 
For histological analysis, we sent three adult MAP1S knockout mice and their 
wild-type littermates, perfused by I. Fischer, to H. Lassmann. The mice were 
four months (male), six months (female), and 13 months (male) old. All organs 
were screened for histological differences.  
In brain and testis, where MAP1S is expressed at highest levels (Orban-Nemeth 
et al., 2005), no histological disparities were found (figure 29 and 30).  
The liver of the four month old male knockout mouse showed disturbed 
organisation of bile ducts. The number of bile ducts seemed increased. In 
addition to bile ducts found in portale triads next to the hepatic portal vein in 
wild-type liver, bile ducts were found widespread in the portal lobule in MAP1S 
knockout liver (figure 31). In the liver of the two other MAP1S knockout mice, 
the organisation of bile ducts appeared normal. 
In all other organs examined, no abnormalities were found in MAP1S knockout 
mice (data not shown).  
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Figure 29. Histological analysis of the brain did not show any differences 
between wild-type and MAP1S knockout mice. Frontal sections through the cerebral 
white matter and corpus callosum were stained with hematoxylin and eosin (a,b), luxol 
fast blue myelin staining (c,d) or Bieschowsky silver impregnation for axons (e,f). The 
cerebral cortex (CX), the corpus callosum (CC) and the hippocampus of a normal wild-
type mouse brain (a,c,e) and a MAP1S knockout mouse (b,d,f) showed normal 
architecture of myelinated fiber tracts including the corpus callosum (a-f) and axons  
(e,f, dark brown). The corpus callosum in wild-type brain appeared thicker due to an 
oblique section. Sections through the cerebellar cortex were stained with hematoxylin 
and eosin (g,i) and Bielschowsky silver impregnation (h,j). No differences between 
wild-type and MAP1S knockout mice were found.   
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Figure 30. Histological analysis of the testis did not reveal any differences 
between wild-type and MAP1S knockout mice. Sections through testis were stained 
with hematoxylin and eosin. Leydig cells (blue arrow), spermatocytes (black arrow), 
and spermatids (black arrowhead) were organised normally. No abnormalities were 
found in MAP1S knockout mice.  
 
 
 
                        
              
 
 
 
 
 
Figure 31. Histological analysis of the liver showed disturbed organisation of 
small blood vessels or bile ducts in one MAP1S knockout mouse. Sections 
through the liver were stained with hematoxylin and eosin. Wild-type liver sinusoids and 
bile ducts (black arrow) were organised normally. In the liver from one homozygous 
knockout neo mouse, bile ducts were found not only in portale triads next to the hepatic 
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portal vein as in wild-type liver (black arrow), but additionally widespread in the portal 
lobule (white arrows).   
 
The expression pattern of MAP1A and MAP1B in the brain of 
MAP1S knockout mice  
 
As no abnormalities were found in the brain of MAP1S knockout mice, MAP1S 
seemed to be dispensable for brain development. To analyse if the loss of 
MAP1S might be compensated for by other proteins of the MAP1 family, 
immunoblot analysis was performed. Total protein lysates from whole brain, 
pieces of the cortex and the cerebellum were extracted. In immunoblot analysis 
the expression pattern of the MAP1A light chain was not altered in the brain of 
homozygous knockout mice (figure 32).  
 
  
 
 
 
 
 
 
 
 
 
Figure 32. The expression pattern of the MAP1A light chain was not altered in the 
brain of MAP1S knockout mice. 80µg of protein (total lysate) extracted from the 
brains of adult wild-type (wt) and MAP1S knockout (ko) mice were analysed by SDS-
PAGE and immunoblotting with antibodies against MAP1S heavy chain (anti-MAP1S 
HC), tubulin (anti-tubulin) and MAP1A light chain (anti-MAP1A LC). The positions of the 
respective proteins are indicated. MAP1S was expressed in the whole brain (brain), in 
the cerebral cortex (cortex) and in the cerebellum (cereb) in wild-type, but not in 
MAP1S knockout mice. Tubulin staining served as internal control. The expression 
level of the MAP1A light chain showed no differences between wild-type and MAP1S 
knockout mice.  
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Additionally, immunoblot analysis to detect the expression of the MAP1B light 
chain was performed. The expression pattern of the MAP1B light chain was not 
altered in the brain of homozygous knockout mice (figure 33).    
 
 
 
 
 
 
 
 
Figure 33. The expression pattern of the MAP1B light chain was not altered in the 
brain of MAP1S knockout mice. 80µg of protein (total lysate) extracted from the 
brains of adult wild-type (wt) and MAP1S knockout (ko) mice were analysed by SDS-
PAGE and immunoblotting with affinity-purified antibodies against tubulin (anti-tubulin) 
and against MAP1B light chain (anti-MAP1B LC). The positions of the respective 
proteins are indicated. Tubulin staining served as internal control. The expression level 
of the MAP1B light chain showed no differences in wild-type and MAP1S knockout 
mice.  
 
MAP1S knockout DRGNs 
 
As previously mentioned, MAP1B is expressed in DRGs and cultured DRGNs 
lacking MAP1B are able to regenerate their axons, but show enhanced neurite 
branching and impaired axonal turning behaviour (Bouquet et al., 2004). 
MAP1S too was shown to be expressed in DRGs (Ding et al., 2006b). To 
analyse the influence of MAP1S on axon regeneration, DRGNs from MAP1S 
knockout mice and their wild-type littermates were isolated, cultured, fixed, 
stained for tubulin and analysed by confocal microscopy. All pertrusions longer 
than one diameter of the associated cell body were counted as axons. DRGNs 
from MAP1S knockout mice displayed a shift towards cells with more than one 
axon. Whereas 42% of the wild-type DRGNs elaborate a single branched axon, 
significantly less (29%, p=0.03, t-test) of the DRGNs isolated from MAP1S 
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knockout mice display just one axon, while cells with two or more axons 
emenating from the cell body appear to be more frequent (figure 34).  
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Figure 34. DRGNs from MAP1S knockout mice displayed a shift towards cells 
with more than one axon. DRGNs of adult wild-type and homozygous knockout mice 
were cultured for 24 to 48 hours, fixed, and stained for tubulin and analysed by 
confocal fluorescence microscopy. (A) Representative immuno-fluorescence pictures 
were taken from DRGNs showing cell bodies with 1, 2, 3 or 4 axons per cell body. All 
extensions which were longer than one diameter of the associated cell body were 
counted as axons. (B) From each genotype at least 100 cells were counted in three 
independent experiments and presented as mean values with error bars representing 
standard deviations. 42% of the DRGNs of wild-type mice elaborate a single axon, 
DRGNs of MAP1S knockout mice show significantly less DRGNs with one axon (29%, 
p=0.03, t-test).    
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Schwann cells provide myelin insulation to axons in the peripheral nervous 
system. MAP1B is expressed in adult Schwann cells and its expression 
increases when they de-differentiate and proliferate after a peripheral lesion and 
migrate into the lesion site. It was shown that MAP1B is is required for provoked 
motility of Schwann cells in migration assays (Bouquet et al., 2007; Ma et al., 
1999).  
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Figure 35. Schwann cells of MAP1S knockout mice did not differ in the number of 
protrusions. Schwann cells from adult wild-type and MAP1S knockout mice were 
cultured for 48 hours, fixed, and stained for p75 and analysed by confocal fluorescence 
microscopy. (A) Representative immunofluorescence pictures were taken from 
Schwann cells showing cell bodies with 2, 3, 4 or 6 protrusions per cell body. All 
processes, which were longer than one diameter of the associated cell body, were 
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counted as protrusions. (B) From each genotype at least 100 cells were counted in 
three independent experiments and presented as mean values with error bars 
representing standard deviations.  
 
Schwann cells from adult MAP1S knockout mice and their wild-type littermates 
were isolated, cultured, fixed, stained for the Schwann cell marker p75 and 
analysed by confocal microscopy. All protrusions longer than one diameter of 
the associated cell body were counted as protrusions. The number of 
protrusions per cell did not differ between MAP1S knockout and wild-type mice 
(figure 35).   
 
MAP1S knockout fibroblasts 
 
To analyse the role of MAP1S during cell cycle, and in cell migration, fibroblasts 
of adult wild-type and MAP1S knockout mice were isolated and cultured. 
Immunoblot analysis confirmed that MAP1S is expressed in fibroblasts of wild-
type, but not in fibroblasts of MAP1S knockout mice (figure 36).  
  
 
 
 
 
 
 
 
 
Figure 36. Immunoblot analysis of the expression of MAP1S in fibroblasts of 
wild-type and MAP1S knockout mice. 80µg of protein (total lysate) extracted from 
fibroblasts from adult wild-type (wt) and MAP1S knockout (ko) mice were analysed by 
SDS-PAGE and immunoblotting with antibodies against MAP1S heavy chain (anti-
MAP1S HC) and against tubulin (anti-tubulin). The positions of the respective proteins 
are indicated. Tubulin staining served as internal control. Protein bands of 100kD 
correspond to the MAP1S heavy chain (HC). MAP1S was expressed in wild-type, but 
not in MAP1S knockout fibroblasts.  
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Cellcycle phase distribution in MAP1S knockout fibroblasts 
 
To explore the role of MAP1S in the cell cycle, fibroblasts of MAP1S knockout 
and wild-type mice were isolated, cultured, and cell cycle FACS analysis was 
performed in the logarithmic growth phase of the cells (figure 37). In wild-type 
fibroblasts, 50% were found in G0/G1 phase, 33% in S phase and 17% in G2/M 
phase. In contrast, 82% of MAP1S knockout fibroblasts were found in G0/G1, 
only 10% in S phase and 9% in G2/M phase. Compared to wild-type fibroblasts, 
MAP1S knockout fibroblasts are significantly overrepresentated in the G0/G1 
phase (p=0.0007, t-test), and significantly underrepresented in S (p=0.002, t-
test) and in G2/M phase (p=0.003, t-test). 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. The cell cycle distribution is altered in MAP1S knockout fibroblasts. 
Fibroblasts isolated from adult wild-type and MAP1S knockout mice were cultured and 
analysed by cell cycle FACS analysis. Results from three independent experiments, 
using fibroblasts isolated from two different wild-type and one knockout mice, were 
calculated and presented as mean values with error bars representing standard 
deviations. In wild-type fibroblasts, 50% of the cells were found in G0/G1 phase, 33% 
in S phase and 17% in G2/M phase. In MAP1S knockout fibroblasts, 82% of the cells 
were found in G0/G1, 10% in S phase and 9% in G2/M phase. MAP1S knockout 
fibroblasts are significantly overrepresentated in the G0/G1 phase (p=0.0007, t-test), 
and significantly underrepresented in the S (p=0.002, t-test) and in the G2/M phase 
(p=0.003).   
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Cell migration in MAP1S knockout fibroblasts 
 
As a potential crosslinker protein between microtubules and actin filaments, 
MAP1S may play a role in random cell movement. Therefore fibroblasts were 
plated and scattered cells were monitored four hours later by video microscopy. 
Analysis of this random migration assay was performed with the ImageJ 
program, tracking single cells and calculating their migration velocity (figure 38). 
No significant differences in random migration velocity were found.   
 
 
 
 
 
 
 
 
 
 
 
Figure 38. MAP1S knockout fibroblasts did not migrate significantly slower than 
wild-type fibroblasts in random migration assay. Fibroblasts from adult wild-type 
and MAP1S knockout mice were plated and isolated cells were monitored 4 hours after 
plating for 5.5 hours. Analysis was performed with the ImageJ program, using manual 
tracking. Migration velocity in µm per minute was calculated from three independent 
experiments using fibroblasts from one wild-type and one knockout mouse and is 
presented as mean values with error bars representing standard deviations. No 
significant differences in random migration velocity were found.   
 
And in vitro wound healing assay was performed to analyse directed cell 
migration. Therefore fibroblasts of MAP1S knockout and wild-type mice were 
isolated, cultured, grown until they reached near confluency, and a scratch was 
made within the monolayer (figure 39). The scratched cell free area was 
monitored and measured at different time points (six to 72 hours after the 
scratch) and the percentage of free area relative to the free area measured 
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immediately after scratching was calculated. 24 hours after the scratch, 39% of 
the scratched area remained cell free in wild-type firoblasts. In MAP1S knockout 
fibroblasts, a significantly larger area, 55% of the scratched area (p=0.03, t-
test), remained cell free. 30, 36 and 42 hours after the scratch, the differences 
were even more significant (p=0.01, p= 0.01, p=0.00002 respectivly, t-test).  
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 39. MAP1S knockout fibroblasts closed the scratched wound slower than 
wild-type fibroblasts. Fibroblasts from adult wild-type and MAP1S knockout mice 
were cultured and grown until they reached near confluence. Then the cell monolayer 
was scratched and pictures of these scratches were taken every 6 to 12 hours. (A) 
Representative pictures from scratched fibroblasts show the scratched cell free area 
from 0 hours (0h) up to 60 hours (60h) after the scratch. Analysis was performed with 
the AxioVision program, measuring the cell free area of the scratch (surrounded in red). 
MAP1S knockout fibroblasts migrated slower. Whereas the scratch wound was closed 
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after 48 hours in wild-type fibroblasts, MAP1S knockout fibroblasts needed 60 hours to 
close a scratch wound of equal width. (B) Cell free areas were measured at different 
time points and presented as mean values of the percentage of free area relative to the 
free area measured immediately after scratching (0h) with error bars representing 
standard deviations (five scratches in two independent experiments, fibroblasts isolated 
from two wild-type and two knockout mice). MAP1S knockout fibroblasts migrated 
slower. Whereas the sratch wound was closed after 48 hours in wild-type fibroblasts, 
MAP1S knockout fibroblast needed 60 hours to close the scratch wound. 24, 30, 36 
and 42 hours after the scratch, differences were significant (p=0.03 (*), p=0.01 (**), p= 
0.01 (**), p=0.00002 (***) respectivly, t-test).  
  
MAP1S knockout fibroblasts migrated slower. Whereas the scratched wound 
was closed after 48 hours in wild-type fibroblasts, MAP1S knockout fibroblast 
needed 60 hours to close a scratch wound of equal width.    
The proper organisation of the cytoskeleton network plays an important role in 
cell migration. To examine, whether the absence of MAP1S affected the 
organisation of microtubules and actin filaments, fibroblasts were cultured, 
fixed, stained for tubulin and actin and analysed by confocal fluorescence 
microscopy (figure 40). The appearance of microtubules and actin filaments 
was unaltered compared to wild-type fibroblasts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. The appearance of the cytoskeleton was not altered in fibroblasts 
isolated from MAP1S knockout mice. Fibroblasts from adult wild-type and MAP1S 
  86 
Foc Adh/1000µm2
0,00
5,00
10,00
15,00
20,00
25,00
1wild-type 
15
25
nu
m
be
r
MAP1S knockout
number of focal adhesions/
1000µm2 cell area
Size of Foc Adh in µm
0,00
1,00
2,00
3,00
4,00
5,00
6,00
7,00
8,00
9,00
1wild-type 
2
8
4
6
focal adhesion size in µm2
MAP1S knockout
µm
2
kn
oc
ko
ut
anti-actin anti-tublin anti-vinculin merge
w
ild
-ty
pe
anti-actin anti-tublin anti-vinculin merge
knockout mice were cultured, fixed, stained for tubulin and actin, and analysed by 
confocal fluorescence microscopy. Representative immunofluorescence pictures were 
taken. No differences were found between MAP1S knockout and wild-type fibroblasts 
in the appearance of microtubules and actin filaments.   
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Figure 41. The number of focal adhesions and their size are not significantly 
altered in fibroblasts isolated from MAP1S knockout mice. Fibroblasts from adult 
wild-type and homozygous knockout mice were cultured for 24 hours, fixed, stained for 
tubulin, actin, vinculin, and analysed by confocal microscopy. Pictures were analysed 
by Image J, measuring size and number of particles stained with vinculin. (A) 
Representative immunofluorescence pictures were taken. (B) The number of focal 
adhesions per 1000µm2 cell area and the size of focal adhesions in µm2 of three 
independent experiments of fibroblasts from three wild-type and three knockout mice 
are presented as mean values with error bars representing standard deviations. The 
number of focal adhesions per 1000µm2 cell area is not significantly reduced (p=0.23, t-
test), the size of focal adhesion is not significantly increased (p=0.06, t-test).   
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Cell migration is regulated partially by the connection between the substratum 
and the actin cytoskeleton. Vinculin, a protein in focal adhesion plaques, is one 
of the proteins involved in this linkage. The dynamic assembly and disassembly 
of focal adhesions plays a central role in cell migration. To explore the influence 
of MAP1S on the formation of focal adhesion, fibroblasts of wild-type and 
MAP1S knockout fibroblasts were isolated, cultured for 24 hours, stained for 
actin, tubulin and vinculin and analysed by confocal microscopy. Pictures were 
analysed by Image J, analysing size and number of particles stained with 
vinculin (figure 41). The number of focal adhesions per 1000µm2 cell area was 
not significantly reduced and the size of focal adhesion was not significantly 
increased.  
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DISCUSSION 
 
While several mice with disrupted MAP1B genes have been available for some 
time (Edelmann et al., 1996; Gonzalez-Billault et al., 2000; Meixner et al., 2000; 
Takei et al., 1997), mice with disrupted MAP1S genes have not been reported 
so far. In this thesis, the generation and characterisation of MAP1S knock out 
mice are described for the first time. 
 
General examination and histological analysis of MAP1S 
knockout mice 
 
As MAP1S is supposed to play an important role in mitosis by binding to 
RASSF1A/Cdc20/APC (Dallol et al., 2007; Song et al., 2005), embryonic 
lethality after knocking out MAP1S was expected. Surprisingly, I found that 
homozygous MAP1S knock out mice are viable and fertile without showing any 
overt phenotype.  
Due to its interaction with VCY2, MAP1S was supposed to play an important 
role in spermatogenesis (Wong et al., 2004). Interestingly, homozygous MAP1S 
knock out mice are fertile and histological analysis revealed that their testis do 
not show any abormalities. Therefore, I can rule out that MAP1S is essential for 
spermatogenesis.  
In brain, like in testis, MAP1S is expressed at a high level. Histological analysis 
of brains of MAP1S knock out mice showed no differences compared to wild-
type mice. According to these results, MAP1S seems to be not essential for the 
development of the brain. The lack of an obvious phenotype of MAP1S 
knockout mice may be explained by potential functional redundancies. 
Developmental plasticity might compensate for the early loss of MAP1S. This 
may be due to functional redundancies at the single gene levels, the genetic 
pathway level or it may involve a systemic adaptive mechanism (Muller, 1999). 
Within the MAP1 family, MAP1A and MAP1B may functionally compensate for 
deficits associated with the loss of MAP1S. In immunoblot analysis the 
expression levels of MAP1A LC and MAP1B LC were not altered in the adult 
MAP1S knockout brain. Nevertheless, a compensatory effect of MAP1A and 
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MAP1B can not be excluded. On the one hand, MAP1A and MAP1B expression 
could be elevated during distinct developmental periods. On the other hand, 
MAP1A and MAP1B could be activated by posttranslational modifications and 
therefore compensate for MAP1S.  
One method to unmask the compensatory effects would be to generate double-
knockout mice. The comparison of phenotypes caused by individual and 
combined gene kockouts would allow the analysis of specific and redundant 
functions of individual family members (Muller, 1999). MAP1B appears to share 
some functions with both Tau and MAP2. Double-knockouts of either MAP1B 
and Tau or MAP1B and MAP2 resulted in more sever phenotypes than those 
seen in single knockouts (Takei et al., 2000; Teng et al., 2001). If MAP1B and 
MAP1S would act in a synergistic fashion, the phentype of double-knockout 
mice should be more severe than in single-knockout mice. Till now, no MAP1A 
knockout mice are available to analyse compensation of MAP1A for MAP1S by 
this approach.  
As MAP1S is expressed in all murine organs examined so far, all organs were 
screened by histological analysis. No abnormalities were found in three mice of 
different age and sex, apart from altered bile ducts in one liver of a four month 
old male mouse. The association between the loss of MAP1S and the increased 
number of interlobular bile ducts aside from portal triads is unclear. The 
epithelial cells of interlobular bile ducts are called cholangiocytes. 
Cholangiocytes may develop during fetal development and in the adult liver. 
During fetal development they emerge from hepatocytes (Cocjin et al., 1996; 
Lemaigre, 2003). In the adult liver cholangiocytes may originate from 
proliferation of pre-existing bile duct cells, from activated and differentiated 
progenitor cells, from cells which entered from the circulation and differentiate to 
liver cells or from bilary metaplasia of hepatocytes (Roskams et al., 2004). 
Endotoxins and inflammatory cytokines, such as lipopolysaccharide (LPS), 
tumour necrosis factor α (TNF-α), and interleukin-1β (IL-1β), lead to stimulated 
secretion of IL-6 in cholangiocytes. Cholangiocytes themselves respond to IL-6 
by enhanced proliferation (Chen et al., 2009; Matsumoto et al., 1994; Park et 
al., 1999; Van Snick, 1990). LPS additionally induces SOCS3, which negatively 
regulates IL-6 signalling and the subsequent phosphorylation of STAT3 (Croker 
et al., 2003; Zou et al., 2008b). Interestingly, MAP1S depletion experiments by 
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siRNA suggested that MAP1S plays an important role in the negative regulation 
of SOCS3 on IL-6 signalling (Zou et al., 2008b). Thus, the increased number of 
interlobular bile ducts in the liver of the MAP1S knockout mouse may occure 
due to the disrupted inhibitory mechanism of SOCS3 in IL-6 signalling pathway. 
Gene targeting studies revealed that SOCS3 and IL-6 are dispensable for 
normal liver development and function under steady-state conditions, but both 
proteins are controlling responses to liver damage or disease (Cressman et al., 
1996; Croker et al., 2003). Perhaps MAP1S is part of this mechanism and plays 
a role in response to liver damage or disease. This may explain why the altered 
liver phenotype was not found in all MAP1S knockout mice. Another reason, 
why this phenotype was only found in one mouse, may be their different genetic 
background. MAP1S knockout mice contained DNA from the 129 and C57BL/6 
strain. To rule out the influences of the mixed genetic background, 
backcrossings would have to be performed. 
 
A                                                              B   
 
 
 
 
 
 
 
 
 
Figure 42. A model for MAP1S mediated effects in liver damage or disease. 
Lipopolysaccharide (LPS), tumour necrosis factor α (TNF-α), and interleukin-1β (IL-1β), 
lead to stimulated secretion of IL-6 in cholangiocytes, which respond to IL-6 by 
enhanced proliferation (Chen et al., 2009; Matsumoto et al., 1994; Park et al., 1999; 
Van Snick, 1990). LPS additionally induces SOCS3, which negatively regulates IL-6 
signalling if MAP1S is available (Croker et al., 2003; Zou et al., 2008b). Both, SOCS3 
and IL-6 seem to control responses to liver damage or disease (Cressman et al., 1996; 
Croker et al., 2003). Thus, the increased number of interlobular bile ducts in the liver of 
the MAP1S knockout mouse may occur in response to liver damage or disease due to 
the disrupted inhibitory mechanism of SOCS3 in IL-6 signalling pathway. 
  91
In mice sent for histological analysis, no tumours were found. MAP1S is 
suspected to play a role in cancerinogenesis, mainly because MAP1S is 
interacting with the tumour suppressor protein RASSF1A (Dallol et al., 2004; 
Song et al., 2005). RASSF1A knockout mice were viable and fertile and were 
prone to spontaneous tumourigenesis at an advanced age, 18 to 20 months. 13 
of 41 RASSF1A knockout mice developed tumours compared to two of 48 wild-
type mice (Tommasi et al., 2005). Due to the young age and limited number of 
mice we analysed, we cannot rule out that MAP1S deficiency effects 
spontaneous tumourigenesis at an advanced age. To clarify the role of MAP1S 
in cancerinogenesis, more mice at an advanced age would have to be 
monitored.    
 
MAP1S knockout DRGNs and Schwann cells 
 
In culture, DRGNs from MAP1S knockout mice displayed a shift towards cells 
with more than one axon. The mechanism determining where and how many 
axons form at the neuronal surface of DRGNs is unclear. In general, neurites 
are thin microtubule-based cell protrusions, which are formed by active 
outgrowth from the cell body and terminate in a dynamic, actin-rich growth cone 
of variable size. Several studies show that both microtubules and actin filaments 
are important in normal neurite initiation. Actin filaments and microtubules 
probably act not only individually, but in a cooperative fashion. Some findings 
suggest that actin filaments decelerate, while microtubules promote neurite 
initiation. Demehlt and Halpain propose that MAPs are a key to neurite initiation 
by altering microtubule function, for example by stabilising and bundling 
microtubules, or by mediating the crosstalk between microtubules and F-actin 
(Dehmelt and Halpain, 2004). MAP1S was shown to stabilise and bundle 
microtubules and to interact with both, microtubules and actin. Therefore, 
MAP1S deficiency may alter microtubule stability and interaction with actin 
filaments and therefore influence neurite initiation. 
Caldron et al. described a correlation between axon outgrowth and the position 
of the centrosome in hippocampal neurons (de Anda et al., 2005; Knoblich, 
2005). In cultured hippocampal neurons the axon arises from the neurite that 
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developes first after mitosis. Opposite the cleavage furrow, centrosomes, the 
Golgi apparatus and endosomes are clustered together close to the area where 
the first neurite forms. Interestingly, neurons with more than one centrosome 
sprout more than one axon (de Anda et al., 2005). The correlation between 
axon outgrowth and the position of the centrosome is found in rat hippocampal 
neurons and also in neurons in the developing eye of drosophila (de Anda et al., 
2005; Knoblich, 2005). Outgrowth in DRGNs may be determined by a similar 
mechanism. Interestingly, MAP1S is localised on the centrosome throughout 
the cell cycle. MAP1S depletion by siRNA causes various mitotic spindle 
abnormalities including the formation of multipolar spindles (Dallol et al., 2007; 
Song et al., 2005). Therefore, the shift towards cells with more than one axon in 
DRGNs from MAP1S knockout mice may be a result of altered centrosomes in 
DRGNs. Analyses of DRGNs stained for centrosomes would reveal the role of 
centrosomes in the neurotigeneses in DRGNs.  
In Schwann cells, the number of processes per cell did not differ between 
MAP1S knockout and wild-type mice. For this reason, I assume MAP1S is not 
involved in the initiation of processes in Schwann cells. One can speculate that 
the initiation of processes in non-neuronal cells differs from the initiation of 
neurites in neuronal cells like DRGNs.  
 
Cell cycle phase distribution in MAP1S knockout fibroblasts 
 
MAP1S was already suspected to play a crucial role in mitosis through its 
interaction with RASSF1A, but results obtained in different labouratories appear 
to contradict each other. Song et al. found that knockdown of MAP1S by short 
hairpin RNA leads to accelerated mitotic progression and increases the number 
of abnormal mitosis (Song et al., 2005). In contrast, Dallol et al. showed that the  
loss of MAP1S mediated by transient treatment with siRNA oligos leads to a 
delay in mitosis and accumulation in the G2/M phase (Dallol et al., 2007). 
MAP1S is known to interact with RASSF1A, which regulates mitosis by 
inhibiting the anaphase-promoting complex (APC)-Cdc20 complex resulting in 
delay of mitosis (Song and Lim, 2004; Song et al., 2004; van der Weyden and 
Adams, 2007). This MAP1S-RASSF1A interaction is thought to be required for 
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the proper control of the APC-Cdc20 complex during mitosis (Song et al., 2004; 
van der Weyden and Adams, 2007). According to these findings, I would expect 
that the loss of MAP1S leads to accelerated mitotic progression, as Song et al. 
found in HeLa cells after down regulating MAP1S by shRNA. Song et al. 
assumed that the interaction with RASSF1A blocks the ability of Cdc20 to 
activate the APC and therefore stabilises cyclin A and B and blocks the mitotic 
progression that usually follows their degradation (Song et al., 2005). My results 
obtained with fibroblasts from MAP1S null mice suggest that true MAP1S 
deficient cells spend significantly more time in the G0/G1 phase relative to S 
and G2/M phases. Therefore, I conclude that the loss of MAP1S results either in 
a G0/G1 arrest or in a G2/M acceleration. As my cell culture experiments 
revealed that MAP1S deficient fibroblasts are growing rather slower than wild-
type fibroblasts (data not shown), I assume that the loss of MAP1S results more 
likely in a G0/G1 arrest than in a G2/M acceleration.  
Thus, my results neither support those of Song et al. nor those of Dallol et al.. In 
both knockdown approaches, a low level of MAP1S protein was still detectable 
(Song et al., 2005), which may explain the discrepancy. My results represent 
the situation in real MAP1S null fibroblasts. According to my findings, I conclude 
that MAP1S plays a role in the regulation of the cell cycle. Surprisingly, MAP1S 
seems to regulate the cell cycle not only via binding to the RASSF1A-APC-
Cdc20 complex, but, additionally, via the G1-S checkpoint. Interestingly, beside 
interacting with the APC-Cdc20 complex, RASSF1A plays also an important 
role at the G1-S checkpoint. Expression of exogenous RASSF1A induces G1 
arrest via inhibiting the accumulation of cyclin D1 protein (Shivakumar et al., 
2002; van der Weyden and Adams, 2007). Rong et al. confirmed these findings 
and found out that the RASSF1A induced G1 arrest is transient. They showed 
that 72h after transfection with constructs encoding RASSF1A, the proportion of 
RASSF1A-expressing G1-arrested cells was significantly reduced, but at the 
same time there was an increase in the population of RASSF1A-expressing 
cells in G2/M phase (Rong et al., 2004). To sum up, overexpressing RASSF1A 
seems to induce cell cycle arrest in both G1 and G2/M phase. It is still unknown 
whether the expression level of MAP1S influences the expression level of 
RASSF1A or the other way around. The likely G0/G1 arrest in MAP1S deficient 
fibroblasts may result from an increased level of RASSF1A.  
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I presume that MAP1S plays an important role in several phases of the cell 
cycle. The complete loss of MAP1S leads to a G0/G1 arrest, whereas a mere 
decrease of the MAP1S level results in accelerated mitotic progression (Song et 
al., 2005) or in a delay in mitosis and accumulation in the G2/M phase (Dallol et 
al., 2007). Therefore, I propose that the level of MAP1S is crucial for proper 
regulation of the cell cycle.  
Interestingly, centrosomes seem to be required for several cell cycle transitions, 
including G1 to S phase, G2 to mitosis and metaphase to anaphase. Doxey et 
al. propose that the loss of centrosome integrity activates a checkpoint that 
inhibits G1/S progression (Doxsey et al., 2005). As MAP1S is localised on the 
centrosome throughout the cell cycle and its depletion by siRNA causes various 
mitotic spindle abnormalities (Dallol et al., 2007; Song et al., 2005), the G0/G1 
arrest in MAP1S deficient fibroblasts may also be caused by disturbed 
centrosome integrity.  
 
Cell migration in MAP1S knockout fibroblasts 
 
In the random migration assay, no significant differences in migration velocity 
were found within 5.5 hours. A longer time period was monitored in the in vitro 
wound healing assay. Whereas wild-type fibroblasts could close the scratched 
wound after 48 hours, MAP1S knockout fibroblast needed 60 hours to close a 
scratch wound of equal width. 24, 30, 36 and 42 hours after the scratch, the 
width of the remaining free scratch area was different for wild-type and MAP1S 
knockout fibroblasts. These results show that the loss of MAP1S leads to slower 
migration of fibroblasts. The migration of cells plays a central role in many 
normal and pathological processes, like embryonic development, wound 
healing, inflammation and tumour metastasis (Huttenlocher et al., 1995). 
Fibroblasts are especially responsible for wound contraction and scar tissue 
formation. The results obtained in the in vitro wound healing assay revealed a 
novel role of MAP1S. The loss of MAP1S seems to impair wound healing.  
During migration a cell polarises, extends protrusions at its front, pulls itself 
forward, and retracts its trailing end cyclically. Therefore the organisation of the 
cytoskeleton constantly changes. The regulated and polarised turn over of the 
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actin cytoskeleton and of the adhesion complexes that link it to the extracellular 
matrix drive cell movement (Small et al., 1996; Small et al., 1998). Fibroblasts 
lacking plectin or vimentin, which are delayed in migration, showed altered 
formation of the actin network and focal contacts (Andrä et al., 1998; Eckes et 
al., 1998). Microtubules themselves (Kaverina et al., 2000; Kaverina et al., 
1998; Small et al., 2002; Small and Kaverina, 2003) and the interplay between 
microtubules and actin filaments are essential for cell motility (Waterman-Storer 
and Salmon, 1999; Rodriguez et al., 2003). Moreover, migrating cells usually 
exhibit a reorganised microtubule cytoskeleton with centrosomes and most 
microtubules orientated towards the leading edge. This reorientation of the 
microtubule-organising center (MTOC) seems to be essential for cell migration 
(Gotlieb et al., 1981; Gundersen and Bulinski, 1988; Kupfer et al., 1982; 
Palazzo et al., 2001). It remains to be seen whether reorientation of the 
microtubule network is impaired in MAP1S deficient fibroblasts.  
MAP1S is known to bind to microtubules and actin filaments and to stabilise 
microtubules (Andrä et al., 1998; Eckes et al., 1998; Orban-Nemeth et al., 
2005). Therefore, we expected to find altered formation of the cytoskeleton in 
MAP1S deficient fibroblasts. Surprisingly, no changes in microtubule and actin 
filament appearance were detectable in immunofluorescence analyses of 
MAP1S knockout dermal fibroblasts. MAP1S was shown to localise on 
centrosomes (Dallol et al., 2007; Song et al., 2005)., and the knockdown of 
MAP1S by siRNA resulted in disrupted MTOCs. Therefore, the loss of MAP1S 
may disturb the positioning of the MTOC. The exact function of the reorientation 
of the MTOC toward the leading edge in migrating fibroblasts remains unclear. 
MAP1S could play an important role in this mechanism.  
For migration, the cell adheres to a substrate and exerts traction. Adhesion 
occurs at specific foci, the focal adhesions. I looked at the formation of focal 
adhesions by staining for vinculin, a focal adhesion component. Although I 
could find a tendency towards less frequent, but enlarged focal adhesions, 
these differences were not significant. Therefore, I can not conclude that the 
loss of MAP1S alteres focal adhesions. Beside their size and number, the 
dynamic of assembly and disassembly of focal adhesions plays a central role in 
cell migration. They have to assemble at the cell front and disassemble at the 
cell rear. As already mentioned, the cell has to exert traction to move. This force 
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is generated by contractile actin bundles pulling on focal adhesions. 
Microtubules specifically target focal adhesions and the targeting frequency is 
inversely proportional to the lifetime of a focal adhesion (Kaverina et al., 1999; 
Kaverina et al., 1998; Krylyshkina et al., 2003; Rodriguez et al., 2003). It is 
conceivable that MAP1S plays a role in the dynamic of assembly and 
disassembly of focal adhesions. More experiments need to be done to clarify 
this open question.  
Rodriguez et al. suggest that microtubules are likely to be linked to focal 
adhesion associated actin filaments by static crosslinkers and grow along actin 
bundles (Krylyshkina et al., 2003; Rodriguez et al., 2003; Salmon et al., 2005). 
MAP1S is a potential crosslinker between microtubules and actin filaments. Its 
loss might restrict the linkage between microtubules and focal adhesion 
associated actin filaments and therefore impair cell migration.  
Interestingly, Dallol et al. showed that overexpression of RASSF1A in various 
cell lines causes the formation of stable circular and acetylated microtubules 
and inhibits cell migration. RASSF1A deficient fibroblasts showed increased 
motility and migration potential (Dallol et al., 2005). MAP1S is interacting with 
RASSF1A (Dallol et al., 2004; Liu et al., 2002; Liu and McKeehan, 2002; Wong 
et al., 2004), but the function of this interaction is unclear. The loss of MAP1S 
may influence the expression level of RASSF1A. The impaired migration in 
MAP1S knockout fibroblasts may result from an increased level of active 
RASSF1A. The exact mechanism by which MAP1S can influence cell migration 
remains to be elucidated in further studies.  
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Figure 43. A summary of potential functions of MAP1S in vivo. MAP1S is known to 
bind to and stabilise microtubules, to bind to F-actin (Orban-Nemeth et al., 2005), to 
localise to centrosomes (Dallol et al., 2007; Song et al., 2005), and to interact with 
RASSF1A (Dallol et al., 2004; Liu et al., 2002; Liu and McKeehan, 2002; Wong et al., 
2004). MAP1S deficiency leads to a shift towards cells with more than one axon in 
DRGNs. Therefore, MAP1S seems to be necessary in neurotigenesis. MAP1S acts 
probably due to its capacity to alter microtubule stability and to interact with actin 
filament, which seems to be essential for neurite initiation (Dehmelt and Halpain, 2004). 
As axon outgrowth correlates with the position of centrosomes (de Anda et al., 2005; 
Knoblich, 2005), MAP1S may influence neurotigenesis through its putative function on 
centrosomes. Moreover, MAP1S deficient fibroblasts migrate slower. Thus, MAP1S 
influences cell migration. As the cytoskeleton formation was not altered in MAP1S 
deficient fibroblasts, MAP1S seems to impair cell migration via another mechanism. I 
propose that the loss of MAP1S may disturb the positioning or functions of reorientated 
centrosomes, which were found to be essential for cell migration (Gotlieb et al., 1981; 
Gundersen and Bulinski, 1988; Kupfer et al., 1982; Palazzo et al., 2001). Since the 
overexpression of RASSF1A inhibits cell migration (Dallol et al., 2005), MAP1S may 
also regulate the level of active RASSF1A by binding to it and therefore accelerating 
cell migration. The regulation of the level of active RASSF1A may also explain the role 
of MAP1S in the G1/S progression, as the loss of MAP1S results in a G0/G1 arrest in 
fibroblasts, what was also found in RASSF1A overexpressing cells (Rong et al., 2004; 
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Shivakumar et al., 2002; van der Weyden and Adams, 2007). Additionally, the 
localisation of MAP1S on centrosomes may be necessary for their integrity, which is 
needed for G1/S progression (Doxsey et al., 2005).   
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MATERIALS AND METHODS 
 
Commonly used buffers 
 
1xPBS (phosphate buffered saline) 10mM KH2PO4/Na2HPO4 pH 7.5, 150mM 
NaCl 
1xSSC (sodium chloride/ sodium citrate): 150mM NaCl, 15mM Na-citrat, pH 7.0 
1xTAE (Tris-acetate-EDTA): 400mM Tris-acetate pH 8.2, 20mM EDTA 
1xTE (Tris-EDTA): 10mM Tris/HCl pH 8.0, 1mM EDTA 
 
DNA METHODS 
 
DNA manipulation and preparation  
 
Basic cloning techniques like DNA restriction digests, ligation of DNA fragments 
and small scale preparation of plasmid DNA from bacteria were performed as 
described by Sambrook (Sambrook et al., 2001). For large scale preparation of 
plasmid DNA JetStar 2.0 Midi columns (Genomed) were used according to the 
manufacturer’s instructions. DNA fragments for cloning or labeling were isolated 
by using the QuiaexII gel extraction kit (Qiagen) or the NucleoSpin ExtractII kit 
(Macherey-Nagel). Dephosphorylation of 5’-ends of vector DNA was carried out 
using the shrimp alkaline phosphatase (SAP) according to the manufacturer’s 
protocol (Boeringer Mannheim GmbH).  
Concentrations of the DNA were measured spectrophotometrically at 260nm.  
 
Agarose gel 
 
0.7-2g of agarose powder was dissolved in 100ml of electrophoresis TAE 
buffer, heated in the microwave oven and cooled down to 60°C. After adding 
ethidium 0.5µg/ml bromide it was poured into a casting tray. 
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Preparation of rubidium chloride competent bacteria and 
transformation 
 
Appropriate bacteria (DH5α, JM109, BL21) were inoculated and grown 
overnight. 5ml of this fresh overnight culture were inoculated into 500ml LB-
medium (Luria Bertani Medium: 10g Bacto-Trypton, 5g Bacto-Yeast extract, 10g 
NaCl per 1000ml, pH 7.5) and shacked at 37°C until an OD600 of 0.5 was 
obtained. The bacterial cells were incubated on ice for 15 minutes, pelleted for 5 
minutes at 5000rpm (GSA rotor, 4°C) and resuspended in 200ml TfbI buffer 
(30mM potassium acetate, 100mM rubidium chloride, 10mM calcium chloride, 
50mM manganese chloride, 15% v/v glycerol, pH 5.8 adjusted with acetic acid). 
The bacterial resuspension was placed again on ice for 15 minutes and 
centrifuged afterwards for 5 minutes at 5000rpm (GSA rotor, 4°C). The pelleted 
cells were resuspended in 20ml TfbII buffer (10mM  MOPS, 75mM calcium 
chloride, 10mM rubidium chloride, 15% v/v glycerol, pH 6.5 adjusted with 
NaOH) put on ice for 15 minutes and aliquoted. The aliquots of competent cells 
were stored at -80°C.       
For bacteria transformation an aliquot was thawed on ice, mixed with around 
1µg of plasmid DNA or ligation mixture and placed on ice for 20 minutes. Then 
the mixture was incubated for 90 seconds at 42°C and afterwards for 90 
seconds on ice. LB-medium was added and the cells were incubated for 1 hour 
at 37°C while gently shaking. Finally bacteria were plated on solid medium with 
appropriate antibiotics.    
 
Isolation of genomic DNA from cells and mouse tails 
 
ES cell clones or 0.5 to 1cm of mouse tails were incubated with 500µl or 750µl, 
respectively, of lysis buffer (50mM Tris pH 8.0, 25mM EDTA pH 8.0, 100mM 
NaCl, 1% SDS, 300µg/ml Proteinase K added fresh) at 37°C overnight. On the 
next day, the lysates were extracted with phenol, phenol/chloroform and 
chloroform. Next, two times volume of EtOH was added and the precipitated 
DNA was spooled out with a sealed Pasteur pipette, put shortly to 70% EtOH 
for washing and resuspended in 100ml of TE and heated for 1 hour at 65°C.  
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Polymerase chain reaction (PCR) 
 
All PCR reactions were performed using the Gene Amp® PCR System 9700 
(Applied Biosystems, Austria). For cloning the PCR were carried out in a final 
volume of 50µl containing 39µl ddH2O, 5µl 10X buffer (Invitrogen), 1µl dNTPs 
(10mM each dNTP), 0.5µl of each primer, 1.5µl of MgCl2, 0.5µl of Taq 
polymerase (Invitrogen) and 2µl of template DNA. For genotyping mice the PCR 
reactions were carried out in a final volume of 25µl containing 16.5µl ddH2O, 5µl 
5xGreen GoTaq® Reaction Buffer (Promega), 0.5µl dNTPs (10mM each dNTP), 
0.5µl of each primer, 0.25µl GoTaq® Polymerase (Promega) and 2µl of template 
DNA. Primer sequences and PCR programs used are listed in table 2. The PCR 
reaction products were analysed on 1-2 % agarose gels.  
 
Primer sequence 5’ -3’  PCR program PCR product 
probe U pA: 
CTCCAGGCCCAGAGACCAGATAATG 
probe U pB: 
GGAGGCTTGAGGGTTCTGCACAATG 
5 min 94°C; 40x  
60 sec 94°C, 60 
sec 65°C, 3 min 
72°C; 7 min 72°C 
probe U: 316bp 
probe D pC: 
GGTTGCTGTCCTTGGGTCCCTATAC 
probe D pD: 
CCAGTTCCATGCTGGCTCAACTCTC 
5 min 94°C; 40x  
60 sec 94°C, 60 
sec 65°C, 3 min 
72°C; 7 min 72°C 
probe D: 349bp 
MAP1S E6/7 fw 
TGTATACCTGGACCTGGCCTACCTG 
MAP1S E6/7 rev 
AAGGCCTCGTCCTGCATGGACAC 
5 min 94°C; 40x  
60 sec 94°C, 60 
sec 65°C, 2 min 
72°C; 7 min 72°C 
MAP1S (Exon 6-
Exon 7): 792bp 
loxPCR fw: 
GATCACATGCATGCTAGCATAACTTCGTA 
TAGCATACATTATACGAAGTTATAAGCTTT
ACATGTGCATACAGAAAAATCTC 
loxPCR rev: 
GGGTCTCTGGTGGAGTTGCCTTCCTAGC 
5 min 94°C; 30x  
60 sec 94°C, 60 
sec 56°C, 6 min 
72°C; 7 min 72°C 
loxP PCR product: 
2.155bp 
(Pfu polymerase 
was used) 
PG1: 
GATTGGCTGGATGGTCAGGGACTTG 
 
 
genotyping mice 
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PG2: 
TCTGGCCATCCGCTTCACATCTCTG 
PG3: 
GATTGGCTGGATGGTCAGGGACTTG 
PG4: 
TGGGATCCGATGGTGTTGTCTAACG 
PG5: 
GGCCACACGCGTCACCTTAATATGC 
 
5 min 94°C; 45x  
45 sec 94°C, 45 
sec 65°C, 2 min 
72°C; 7 min 72°C 
 
Cre sense: 
CCAATTTACTGACCGTACACC 
Cre antisense: 
TAATCGCCATCTTCCAGCAGG 
5 min 94°C; 45x  
45 sec 94°C, 45 
sec 65°C, 2 min 
72°C; 7 min 72°C 
cre: 1029bp 
 
Flp sense: 
GTGGATCGATCCTACCCCTTGCG 
Flp antisense: 
GGTCCCAACCTGCAGCCCAAGCTTCC 
5 min 94°C; 45x  
45 sec 94°C, 45 
sec 65°C, 2 min 
72°C; 7 min 72°C 
flip: 650bp 
Table 2. Primers and PCR programs used to amplify the described PCR 
products.  
 
Southern Blot analysis 
 
24-32µl of genomic DNA (10-15µg) were digested with 30-40 units of the 
appropriate restriction enzyme and separated on a 0.8% agarose gel. The DNA 
was depurinated by soaking the gel once in 500ml of 0.25M HCl for 15 minutes 
and denaturated twice for 15 minutes in 500ml of denaturation buffer (0.5N 
NaOH, 1.5M NaCl). To transfer the DNA to a nylon membrane (PALL 
Biodyne®B, pore size 0.45 µm, rinsed with dH2O before use) semi-dry alkaline 
blotting was performed overnight. On the next day the membrane was 
neutralized for 1 minute in 0.2M Tris/HCl pH 7.5, 1xSSC and the DNA was fixed 
to the membrane with crosslinking using the UV Stratalinker 2400 (Stratagene, 
120mJ/cm2). Prehybridisation was done at 65°C in Church buffer (0.5M sodium 
phosphate pH 7.2, 1mM EDTA, 7% SDS) for 2 to 3 hours. Probes were 
radioactively labeled (α-32P dCTP) with Prime-it II random labelling kit 
(Stratagene). Purification of the labeled probes was done with ProbeQuantTM G-
50 Micro columns (Amersham Pharmacia Biotech). Then the labeled probe was 
  103
denaturated for 5 minutes at 95°C and cooled down in ice for 3 minutes. For 
hybridisation the probe was diluted in 15ml of Church buffer, added to the 
membrane and shacked overnight at 65°C. Afterwards the membrane was 
washed once for 10 minutes and three times for 30 minutes with Church wash 
buffer (12mM sodium phosphate pH 7.2, 1% SDS) at 65°C and exposed to a X-
ray sensitive film (Fuji medical X-ray film HR-E30) at -80°C for 1 to 5 days using 
an intensifying screen.  
 
Cloning of the MAP1S conditional knockout targeting vector 
 
First, genomic mouse DNA was isolated from the RPCI-23_374C22 BAC clone 
(DOE Joint Genome Institute). This BAC clone contained a region about 300kb 
from the C57BL/6J mouse chromosome 8, encoding the MAP1S gene amongst 
others. Bacteria were grown overnight at 37 °C in 150ml LB-medium containing 
20µg/ml chloramphenicol, pelleted and resuspended in 6ml buffer E1 (50mM 
Tris, 10mM EDTA, pH 8.0 adjusted with HCl). 6ml of buffer E2 (200mM NaOH, 
1.0% SDS) were added, gently agitated and incubated for 5 minutes at room 
temperature. Additionally, 6ml of buffer E3 (3.1M potassium acetate, pH 5.5 
adjusted with acetic acid) were added, shacked and incubated for 10 minutes at 
4°C. The lysate was centrifuged for 15 minutes at 6000rpm (GSA rotor, 4°C). 
Then, the supernatant was poured through a filter, mixed with 10ml isopropanol 
and centrifuged for 20 minutes at 10000rpm (HB4 rotor). The dried pellet was 
dissolved in 1.5ml ddH2O and extracted with phenol, phenol/chloroform and 
chloroform. To precipitate the DNA, 100µl of 3M NaAc pH 5.2 and 1ml of 96% 
EtOH were added, mixed and centrifuged for 5 minutes at 12000rpm. The DNA 
pellet was washed twice with 70% EtOH and resolved in 20µl TE.  
After digestion with XhoI, a 13221bp fragment encoding exon 2 to exon 7 from 
MAP1S, was dephosphorylated and cloned into the pAM31 vector, creating the 
plasmid pIK1.  Then, one part of the MAP1S gene (including exon 2 and exon 
3) was synthesised by PCR with loxPCR fw and loxPCR rev primers as 
described in table 2 to add the upstream loxPsite including appropriate 
restriction sites. The PCR product was analysed by sequencing, cloned into a 
pGEMTeasy vector and cut with NsiI. This fragment was then used to replace 
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the NsiI terminated part of the plasmid pIK1 resulting in the plasmid pIK4. To 
insert the second loxP site and the neo selection marker several cloning steps 
were needed. First, the oligo Mun was cloned into the SacI and KpnI sites of the 
pBlueIIKS+ vector resulting in the plasmid pIK2. Second, the pRA11 plasmid 
was cut with NotI and KpnI and cloned into the NotI and KpnI sites of the 
plasmid pIK2 creating the vector pIK5. Then, the pIK5 was cut with MunI and 
the 1246bp fragment was cloned into the EcoRI site of pIK4 resulting in the 
targeting vector. Finally, the targeting vector contained exon 2 to exon 7 from 
MAP1S floxed with loxP sites and downstream a neo resistance flanked with frt 
sites.        
 
Cloning vector/oligo Used for Source 
pBlueIIKS+ cloning vector Stratagene 
pAM31 cloning vector A.Meixner 
pGEMTeasy cloning vector (T/A)  Promega 
oligo Mun fw: (5’-3’) 
CAATTGCGGCCGCGGTACCGC 
TAGCAATTGTGTAC 
oligo Mun rev: (5’-3’) 
ACAATTGCTAGCGGTACCGCG 
GCCGCAATTGAGCT 
synthetic oligonucleotides 
were annealed to oligo Mun 
and used for cloning  
VBC Biotech 
pRA11 source for a loxP site and a 
frt flanked neo resistance  
R. Ackerl 
Table 3. Plasmids and oligos used for cloning the MAP1S conditional knockout 
targeting vector. 
 
PROTEIN METHODS 
                   
Preparation of cell extracts 
 
Cells grown on 6 or 10cm dishes were washed with PBS and 100µl to 250µl of 
SDS sample buffer (100mM Tris/HCl pH 6.8, 4% SDS, 20% v/v glycerol, 12mM 
EDTA, 0.2% bromphenol blue, 0.3% DTT and complete Mini protease inhibitor 
tablets (Roche Diagnostics)) were added. Then, the cells were scraped with a 
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cell scraper, transferred to an eppendorfer tube and sonicated 3 times 20 
seconds at 50% of intensity. Samples were heated at 80°C for 5 minutes and 
used immediately or stored at -20°C.  
 
Preparation of tissue extracts 
 
Mouse tissues were homogenized in 100µl/10mg SDS sample buffer (100mM 
Tris/HCl pH 6.8, 4% SDS, 20% v/v glycerol, 12mM EDTA, 0.2% bromphenol 
blue, 0.3% DTT and complete Mini protease inhibitor tablets (Roche 
Diagnostics)) and sonicated 3 times 20 seconds at 50% of intensity. Samples 
were heated at 80°C for 5 minutes and used immediately or stored at -20°C. 
Approximately 10-20µl of the protein extracts were subjected to SDS-PAGE. 
 
Purification of microtubule proteins   
 
Brains from 1 to 4 day old mice were homogenised with a glass-teflon 
homogeniser in 100µl of ice cold polymerisation buffer (0,1M Pipes, 2mM 
EGTA, 1mM MgCl2,1mM GTP, pH 6.8) per 100mg of tissue. Homogenates 
were centrifuged at 30000rpm (TLA-45, Beckman) for 15 minutes at 4°C and 
the supernatant was centrifuged again at 44000 rpm (TLA-45, Beckman) for 30 
minutes at 4°C. In the next step the clear supernatant was mixed with an equal 
volume of 8M glycerol in polymerisation buffer. The mixture was incubated at 
37°C for 30 minutes and then centrifuged at 44000rpm (TLA-45, Beckman) for 
30 minutes at 35°C. The pellet was resuspended in ice cold polymerisation 
buffer, incubated on ice for 30 minutes and centrifuged at 44000 rpm (TLA-45, 
Beckman) for 30 minutes at 4°C. The supernatant was mixed with the same 
amount of 8M glycerol in polymerisation buffer and the sample was heated to 
37°C for 30 minutes. After additional centrifugation at 44000rpm (TLA-45, 
Beckman) for 30 minutes at 35°C the supernatant was harvested. The obtained 
pellet contained microtubules and microtubule associated proteins. It was 
resuspended in polymerisation buffer and used immediately or stored at -80°C.  
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When this procedure was used to test acetylation of microtubule associated 
proteins, 1mM to 10mM sodium putyrat were added in all buffers to stabilize 
acetylation. 
 
Determination of protein concentration 
 
Protein concentration was measured according to the Bradford method 
(Bradford, 1976). 100mg Coomassie Brilliant Blue G-250 was dissolved in 50ml 
95% EtOH, 100ml 85% phosphoric acid were adjusted to 1000ml with ddH2O. 
This solution was filtered and stored at 4°C. To 1ml of this Coomassie solution 
100µl of (diluted) protein sample was added. After short mixing and incubation 
at room temperature, the absorbance was measured at 595nm using a 
spectrophotometer. Dilutions of a BSA stock solution were used to produce a 
calibration curve.    
 
Pulse-chase labeling of adherent cells with 35S methionine and 
35S cysteine 
 
To determine the cleavage time of MAP1S, N2a cells were pulse chase labeled 
and analysed by immunoprecipitating.  
5x106 N2a cells were seeded on 10 cm dishes. After washing twice with -Meth/-
Cys media (DMEM –Meth/-Cys (Invitrogen), 10% dialysed FCS, 10mM HEPES) 
and incubated with DMEM -Meth/-Cys for 15 min. Then the media was replaced 
to prewarmed 10ml pulse-labeling media (DMEM -Meth/-Cys, 2mCi 35S 
meth/cys) and incubated for 5 to 30 minutes. After removing the pulse-labeling 
media, cells were washed twice with growth media (DMEM, 10% FCS, 2mM 
L-glutamate and 50U/ml penicillin/streptomycin) containing 0.5mM 
Cyclohexamide and incubated in this media for 1 to 48 hours.  
Then, cells were analysed by immunoprecipitating as described under co-
immunoprecipitating by additionally taking radioactivity related security 
measures.  
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Immunoblotting 
 
Analysis of protein samples were carried out on 4-12% SDS-PAGE according to 
the protein size as described by Sambrook (Sambrook et al., 2001). Proteins 
were transferred to a nitrocellulose membrane (0.2µM, Schleicher Schuell) in 
transfer buffer (48mM Tris, 40mM glycine, 20% methanol) using BioRad Semi-
Dry Electrophoretic Transfer Cell (Biorad) for 15-30 minutes at 15V. The 
efficiency of the transfer was controlled by reversibly staining with Amidoblack 
solution (0.1% Amidoblack, 45% EtOH, 10% Acetic Acid). Then the membrane 
was blocked in 2% BSA in PBS/0.25% Tween 20 for 1 hour at room 
temperature, washed three times with PBS/0.25% Tween 20 and incubated for 
2 hours with primary antibodies suitably diluted in 1% BSA/PBS/0.25% Tween 
20. The washing steps were repeated and the antibodies were visualized either 
using the appropriate horse radish peroxidase (HRP)-conjugated antibodies and 
the ECL-detection system (Pierce) or alkaline phosphatase (AP)-conjugated 
antibodies (Promega, Germany) and incubating the membrane in AP- buffer 
(100mM Tris/HCl pH 9.6, 100mM NaCl, 5mM MgCl2; 90µlNBT (nitroblue 
terazolium chloride, 50mg/ml in 70% DMF) and 45µl BCIP (5-bromo-4-chloro-3-
indolyl phosphate, 50mg/ml in 100% DMF) were added per 10ml AP-buffer). 
Primary and secondary antibodies are listed in table 5 and table 6. 
 
Co-Immunoprecipitation 
 
Cell extracts or mouse brain lysates were homogenized in 1ml of ice cold TEN 
buffer (100mM Tris/HCl pH 7.5, 100mM NaCl, 10mM EDTA, 0.1mM DTT and 
Complete Mini protease inhibitors tablets (Roche Diagnostics)) at 4°C with 
motor driven glass-teflon homogenizer. Homogenates were centrifuged at 
14000rpm at 4°C and the supernatants were precleared with 1/5 volume of 
Protein A sepharose beads (Amersham Pharmacia Biotech, USA) pre-treated 
with 2% BSA for 3 hours at 4°C. Unspecific bound proteins were removed by 
centrifugation at 1500rpm for 5 minutes at 4°C. All supernatants were then 
incubated overnight at 4°C with 1µg/ ml if indicated antibodies followed by an 
additional incubation with 1/5 volume of Protein A sepharose beads for 3 hours. 
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Immune complexes were collected by centrifugation at 1500rpm, washed 3 
times with TEN buffer containing protease inhibitors and eluted from beads by 
heating in 50µl SDS sample buffer (100mM Tris/HCl pH 6.8, 4% SDS, 20% v/v 
glycerol, 12mM EDTA, 0.2% bromphenol blue) containing 5% 
2-mercaptoethanol. Finally samples were analysed via immunoblotting.      
 
Blot overlay assay 
 
0.5-1µg of recombinant proteins were loaded on 4-12% SDS-PAGE according 
to the protein size as described by Sambrook (Sambrook et al., 2001), 
separated and transferred to a nitrocellulose membrane (0.2µM, Schleicher 
Schuell, Germany) in transfer buffer (48mM Tris, 40mM glycine, 20% methanol) 
using BioRad Semi-Dry Electrophoretic Transfer Cell (Biorad) for 15- 30 
minutes at 15V. After staining with amidoblack to control the protein transfer, 
the membranes where destained and blocked for 1 hour at room temperature in 
2% BSA in overlay buffer (1xPBS, 0.1% Tween 20, 150mM NaCl). After 
washing three times for 5 minutes in overlay buffer, the blots were incubated for 
2 hours with 0.1µg/ml recombinant protein in 1% BSA in overlay buffer at room 
temperature. After repeated washing in overlay buffer the membrane was 
incubated with suitable diluted primary antibody in overlay buffer for 1.5 hours at 
room temperature. The immune complexes were detected using appropriate 
alkaline phosphatase (AP)-conjugated (Promega) or horse radish peroxidase 
(HRP) conjugated antibodies (Pierce).         
 
CELL CULTURE, IMMUNOFLUORESCENCE MICROSCOPY 
 
Maintenance of cell lines 
 
Frozen cells stored in liquid nitrogen were thawed in a 37°C water-bath, diluted 
in 10ml of growth medium (DMEM, 10% FCS (Fetal Calf Serum), 2mM 
L-glutamate and 50U/ml penicillin/streptomycin), centrifuged at 1000 rpm 
(Heraeus Megafuge) for 3 minutes at room temperature and resuspended in 
growth medium. PtK2, NIH3T3 and N2a cells were cultured on plastic dishes in 
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growth medium at 37°C in a humidified atmosphere containing 5%-8.5% CO2. 
When cell reached confluence, they were washed with PBS and incubated with 
trypsin (0.05% trypsin, 0.2% EDTA) for 5 minutes at 37°C. The trypsinisation 
was inhibited by adding the double amount of growth medium. Cells were 
centrifuged, resuspended in growth medium and splitted into new culture 
dishes. For freezing, cells were trypsinised, pelleted, resuspended in freezing 
medium (growth medium containing 10% DMSO) and aliquoted into cryotubes 
(Nunc). The cryotubes were stored at -80°C for 1 day and then put into a liquid 
nitrogen tank.  
 
Transfection of mammalian cells using FuGENE6 
 
The FuGENE6 (Roche Diagnostic) is a lipid based transfection reagent used for 
transfection of a wide range of eukaryotic cells because of its high efficiency 
and minimal cytotoxicity. 12 to 24 hours prior to transfection, cells were seeded 
on glass coverslips in the wells of a standard 24-well plate (for 
immunofluorescence analysis) or on 10cm plastic dishes (for protein analysis). 
Tet-transactivator dependent expression constructs were cotransfected with 
pTetTA in ration 1:6 Tet responsive expression vector: Tet transactivator 
pTetTA. The DNA-FuGENE6 complex was prepared in polypropylene tubes. 
Before use, the FuGENE6 was warmed to room temperature and mixed well. 
For each well for immunofluorescence analysis, 0.5µg of DNA mixture in 25µl 
DMEM was mixed with 1.5µl FuGENE6 and incubated for 30 minutes at room 
temperature. Then solution was diluted in 75µl of Optimem (Invitrogen) and 
added drop- wise to the middle of the well. For protein analysis 4µg of DNA and 
9µl of FuGENE6 in 75µl DMEM were required. After 30 minutes incubation at 
room temperature, 225µl of DMEM was added and the mixture was transferred 
to the middle of the culture dish. After gentle mixing the plates were incubated 
under appropriate conditions for the cell line used.  
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Construct Encoding for Source 
pHS1 C-myc tagged mouse MAP1S FL (aa 1-973) Z. Orban-Nemeth 
pHS9 C-myc tagged mouse MAP1S LC (aa 755-973) Z. Orban-Nemeth 
pAT11 C-myc tagged mouse MAP1S HC (aa 1-755) A. Trancikova 
pMT5 C-myc tagged rat MAP1B FL (aa 1-2459) M. Tögel 
pMT7 C-HA tagged rat MAP1B N-terminus (aa 1-508) M. Tögel 
pMT22 C-myc tagged rat MAP1B LC (aa 2210-2459) M. Tögel 
pMT11 C-HA tagged rat MAP1B LC C-terminus (aa 2336-
2459) 
M. Tögel 
pMT11 
C2354S 
C-HA tagged rat MAP1B LC mutated C-terminus (aa 
2336-2459) 
A. Trancikova 
pMT11 
C2457S 
C-HA tagged rat MAP1B LC mutated C-terminus (aa 
2336-2459) 
A. Trancikova 
pMT19 C-myc tagged uncleavable rat MAP1B FL (aa 1-
2459) 
F. Propst 
pAH1 C-HA tagged rat MAP1A LC (aa 2554-2774) F. Propst 
nNOS N-HA tagged human nNOS (aa 3-217) A. Trancikova 
Table 4. Tet-transactivator dependent expression constructs used for 
transfection of mammalian cell lines.   
 
Activation and inhibition of nitrosylation in cultured cells 
 
For the activation of nitrosylation cells were cultured and treated with S-Nitroso-
N-acetylpenicillamin (SNAP, Calbiochem) at a final concentration of 100µM for 
1 to 4 hours at 37°C in the dark.  
The nNOS inhibitor N-ω-propyl-L-arginine (NPA, Tocris) was added at a final 
concentration of 1mM for 30 minutes to 1 hour.  
 
Immunofluorescence microscopy of cells 
 
PtK2, N2a or NIH3T3 cells were grown on plastic dishes or glass coverslips. 
When the cells reached the desired density, they were washed with PBS and 
incubated with 4% PFA in PBS for 20 minutes at room temperature, washes 
three times with PBS and incubated for 2 minutes with prechilled methanol on a 
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prechilled (-20°C) metal block for fixation and permeabilizing. Cells were 
washed again three times with PBS and in the case of cell growth on plastic 
dishes they were divided into sections with a hydrophobic isolator pen 
(Lipshaw). For blocking of unspecific binding sites, coverslips or sections of 
plastic dishes were incubated with 2% BSA in PBS for 1 hour at room 
temperature. After washing with PBS, primary antibodies diluted in 1% BSA in 
PBS were added for 1 hour at room temperature. Cells were washed three 
times with PBS and incubated with fluorescence-labeled secondary antibodies 
for 1 hour at room temperature under light protection. They were washed again 
with PBS and additionally with ddH2O. 8µl of moviol was added either on the 
sections and then covered with glass coverslips or the moviol was placed on a 
glass slide and the coverslip with the cells was put upside down on it. Samples 
were stored at 4°C.       
 
Isolation and cultivation of dissociated adult DRG neurons 
 
Mice were anesthetized with IsoFlo (Abbott) and killed by decapitation. Skin and 
muscles beside the vertebra were removed, vertebra was opened and the 
spinal cord was taken out.  
The cultivation of mouse DRG neurons was performed according to the protocol 
of Tonge (Tonge et al., 1997). DRG neurons were harvested in F-12 medium 
and cut into small pieces before enzymatic dissociation by collagenase solution 
(for DRG neurons from 1 mouse: 200µl collagenase (4000U/ml, Sigma), 800µl 
F-12 medium, 20µl horse serum) for 2 hours at 37°C. Then the solution was 
removed and DRG neurons were incubated with 1ml trypsin/DNAase solution 
(500µl Trypsin (0.05% trypsin, 0.2% EDTA), 20µl DNAse1 (1µg/µl), 480µl PBS) 
for 15 minutes at 37°C. The trypsinisation was stopped with 2ml stop solution 
(1.6ml F-12 medium, 400µl horse serum) and DRG neurons were triturated 
several times with narrowed Pasteur pipettes. Cells were harvested with 
centrifugation at 800rpm (Heraeus Megafuge) for 5 minutes and washed twice 
with F-12 medium. Finally DRG neurons were resuspended in growth medium 
(F-12 medium supplemented with N3 (Romijn et al., 1981), 5% horse serum, 
40% glucose, penicillin/streptomycin (Bottenstein and Sato, 1979) and plated on 
  112
poly-L-lysin (10µg/ ml, Sigma) and mouse laminin (10µg/ ml, Sigma) precoated 
coverslips with a density of 100 cells/cm2. Cells were incubated for 24-48 hours 
at 37°C in a humidified atmosphere containing 5% CO2. For 
immunofluorescence analysis, DRG neurons were fixed in 4% PFA, 11% 
sucrose in a PBS: growth medium mixture 1:1 for 45 minutes at room 
temperature. After washing several times with PBS, cell were permeabilized 
and blocked with blocking solution (5% BSA in PBS) containing 0.3% 
TritonX100 for 1 hour at room temperature or overnight at 4°C. Cells were 
washed with PBS, incubated with primary antibodies diluted in 5% BSA in PBS 
for 3 hours at room temperature, washed again and incubated with secondary 
antibodies for 2 hours at room temperature under light protection. The samples 
were washed with PBS and finally with ddH2O and the coverslips were mounted 
on glass slides with moviol. Samples were stored at 4°C.      
 
Isolation and cultivation of adult Schwann cells 
 
Mice were anesthetized with IsoFlo (Abbott) and killed by decapitation. Then 
sciatic and trigeminal nerves were removed from mice and used immediately or 
frozen in 10% DMSO in FCS. Nerves were washed in DMEM-F12 and placed in 
degeneration media (DMEM with high glucose, 10% FCS, 50µg/ml gentamycin, 
2.5µg/ml fungizone, 2µM forskolin, 10ng/ml heregulin-β1). Half of the media 
was changed every third day for two weeks. Then the nerves were rinsed three 
times in PBS-/- and transferred to a 80cm2 flask with 10ml dissociation media 
(L-15 (Gibco), 130U/ml collagenase typ I, 2.5mg/ml dispaseI, 50µg/ml 
gentamycin, 2.5µg/ml fungizone, 50U/ml penicillin/streptomycin) for 3.5 hours at 
37°C, agitating every hour. Then 20ml stop solution (DMEM, 10% FCS) were 
added and nerves were dissociated by pipetting with a narrowed Pasteur 
pipette. Cells were centrifuged, resuspended in N2-HRG media (DMEM F-12, 
1ml/100ml N2 supplement (Gibco), 50µg/ml gentamycin, 2.5µg/ml fungizone, 
2µM forskolin, 10ng/ml heregulin-β1) and plated on poly-L-lysin (10µg/ml, 
Sigma) and mouse laminin (10µg/ml, Sigma) precoated 6cm dishes. On the 
next day the supernatant was plated on precoated coverslips. The adherent 
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cells were trypsinised and plated on precoated coverslips for further 
immunofluorescence analysis.    
 
Isolation and cultivation of adult fibroblasts   
 
Mice were anesthetized with IsoFlo (Abbott) and killed by decapitation. The 
back of the mouse was shaved and rinsed with 70% of EtOH to remove all 
hairs. Skin samples with a size around 2-3cm2 were excised and incubated in 
0.3% trypsin in PBS for 20 hours at 4°C. On the next day the epidermis was 
scraped of, the dermis was washed in PBS and cut into small pieces with 
surgical scalpels. The small pieces were incubated for 2 hours with 3ml of 
collagenase (1000U/ml, Sigma) at 37°C, agitating every 20 to 30 minutes. 3ml 
of cold growth medium (DMEM, 10 % FCS and 50U/ml penicillin/streptomycin) 
were added to stop the reaction and the cells were vortexed vigorously to 
release the fibroblasts from collagen fibres. The suspension was passed 
through a 100µm nylon mesh to remove dermal debris, centrifuged with 800rpm 
(Hereaus Megafuge) for 10 minutes at 4°C and resuspended in growth medium. 
The fibroblast suspension was then plated in a 5cm dish. For cultivation the 
growth medium was changed every second day and the cells were splitted, 
frozen around passage 4 and thawed as described above.   
 
In vitro wound healing assay 
 
Primary adult fibroblasts were seeded and grown till near confluency. With a 
sterile pipette tip a scratch was made with in the monolayer. Then, the migration 
od cell swas measured over a time of 72 hours with the scratch serving as a 
reference point. The same spot was photographed every 6 hours.  Analysis was 
performed with the AxioVision program, measuring the cell free area of the 
scratch. 
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Maintenance of embryonic stem (ES) cells 
 
ES cells were cultured at 37°C in a humidified atmosphere containing 8.8% CO2 
in ES cell medium (high glucose DMEM, 10% FCS (Gibco), 1xNon Essential 
Amino Acids, 1mM Sodium pyruvate, 2mM L-glutamin, 1xpenicillin/ 
streptomycin solution, 0.05mM mercaptoethanol and 1000U/ml ESGRO LIF 
(Chemicon)). The medium was changed every day. Cells were maintained as 
described previously for cell lines with the difference that they were grown on 
confluent layer of mitomycin C treated G418-resistant primary embryonic 
fibroblasts. Therefore MEFs were seeded onto the appropriate culture dish, 
grown up to confluence and treated with MEF medium (DMEM, 10% FCS, 2mM 
L-glutamin, 1xpenicillin/streptomycin solution) and 10µg/ml mitomycin C for 2 
hours before ES cells were split. ES cells were trypsinised for 3 to 5 minutes at 
37°C, resuspended with ES cell medium to get a single cell suspension and 
split 1:3 to 1:5.  
 
Electroporation of ES cells with targeting vector     
 
DNA of the targeting vector was prepared following Qiagen EndoFree Plasmid 
Maxi (Qiagen) protocol and redissolved in 100µl endotoxin-free TE under sterile 
conditions. 100µg of the targeting vector was digested in a final volume of 100µl 
overnight at 37°C. The DNA was extracted with phenol chloroform as described 
above and precipitated with 1/10 volume of 3M Na-acetate pH 5.0 and two 
volumes of ethanol. The precipitated DNA was washed with 70% ethanol, air 
dried and dissolved in 40µl PBS for 10 minutes at 37°C.  
For one electroporation 107 ES cells or around five 10cm dishes of exponentially 
growing ES cells were needed. Cells were washed with PBS, trypsinised, 
centrifuged at 1000rpm for 5 minutes, washed twice with PBS and resuspended 
in 800µl PBS. 20µg linearised targeting vector was added and the mixture was 
transferred in a sterile electroporation cuvette (Biorad) and an electric pulse was 
applied at 260V and 500µF (Biorad Gene Pulser, Biorad). Cell suspension was 
incubated 10 minutes at room temperature after pulsing, resuspended in ES cell 
medium and plated at a density of 2x106 cells per 10cm dish. 24 hours after 
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electroporation selection with 300µg/ml G148 was started. Growing ES cell 
colonies were microscopically inspected and ES cell medium containing 
300µg/ml G148 was changed every day. After 7 to 9 days colonies were picked 
by using a yellow tip of a gilson pipette and transferred to a 96-well microtiter 
plate. 30µl of 1xtrypsin (Gibco) was added to each well and the plate was 
incubated for 5 minutes at 37°C. 60µl of ES cell medium was added to stop 
trypsinisation and cells were transferred into a 24-well plate and grown there for 
2-4 days. Almost confluent cultures were trypsinised (300µl 1x trypsin; 750µl ES 
cell medium). Half of the cell suspension was frozen immediately at -80°C with 
500µl of ES freezing medium (ES cell medium containing 20% DMSO and 40% 
FCS). The rest was transferred onto gelatine coated 24-well-plate. These cells 
were then used for preparation of genomic DNA and genotypic analysis of the 
ES clones. 
 
Blastocyst injection of ES cells 
 
The ES cells were thawed and plated on a 6-well-plate before blastocyst 
injection. For harvesting, cells were washed twice with PBS, trypsinised, 
centrifuged and resuspended in 2ml of medium. As described by Hogan (Hogan 
et al., 1986) the blastocysts were isolated and collected from C57BL/6 females 
at 3.5 days p.c. ES cells were injected into blastocysts and then transferred to 
female C57BL/6/CBA recipient mice by H. C. Theussl and J. Woitschechowski.  
 
ANIMALS 
 
Generation and maintenance of MAP1S (conditional) knockout 
mice 
 
ES cell clones were injected into C57BL/6 blastocysts. Chimeric male founder 
mice were backcrossed to C57BL/6 females to obtain heterozygous mice. 
Heterozygous offsprings were paired to obtain homozygous conditional 
knockout mice for further breeding with cre mice lines.  
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Additionally chimeric male founder mice were paired with cre deleter mice 
obtain heterozygous knockout mice. These heterozygous offsprings were paired 
to obtain homozygous conditional knockout mice for further analysis. 
All mice were kept under standard housing conditions at the animal facility of 
the Max F. Perutz Laboratories (University of Vienna).  
Offsprings were screened by Southern Blot or PCR analysis (or both) of tail 
DNA as described in chapter DNA methods.  
 
ANTIBODIES 
 
All primary and secondary antibodies used for immunoblotting or 
immunofluorescence are listed in table 5 and table 6. Antibodies used for 
immunoblotting were diluted in 1%BSA in PBS/0.25% Tween 20, for 
immunofluorescence antibodies were diluted in 1% BSA in PBS.    
 
Antigen Name/Clone Source Species IF WB 
α-tubulin B512 Sigma mouse 1:2000 1:5000 
α-tubulin   rat 1:500  
α-/β-actin AC75/15 Sigma mouse 1:400 1:1000 
HA 3F10 BM rat 1:300  
N-epsil acety lysin Ab409/11A1 Abcam mouse  1:1000 
nNOS NOS1 (R20) Santa Cruz rabbit 1:500 1:1000 
MAP1A HC HM-1 Biogenesis rabbit  1:1000 
MAP1A LC 892 A.Meixner rabbit  1:1000 
MAP1B HC 891 A.Meixner rabbit 1:200 1:800 
MAP1B LC LC1A M.Tögel rabbit 1:200 1:1000 
MAP1S HC  Z.OrbanNemeth rabbit 5µg/ml 2.5µg/ml 
MAP1S LC  Z.OrbanNemeth rabbit 5µg/ml 2.5µg/ml 
myc (IF) myc 1/2 M.Tögel rabbit 1:300  
myc (WB) myc 3/4 M.Tögel rabbit  1µg/ml 
vinculin vin-11-5 Sigma mouse 1:400  
Table 5. List of primary antibodies. 
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Antigen Source Species IF WB 
Alexa 488-anti-mouse IgG Mol. Probes goat 1:1000  
Alexa 488-anti-rabbit IgG Mol. Probes goat 1:1000  
AP-anti-mouse IgG Jackson lab. goat  1:5000 
AP-anti-rabbit IgG Jackson lab. goat  1:5000 
Cy5-anti-rat IgG Mol. Probes goat 1:1000  
HRP-anti-mouse IgG Jackson lab. goat  1:10000 
HRP-anti-rabbit IgG Jackson lab. goat  1:10000 
Texas red-anti mouse IgG Mol. Probes goat 1:1000  
Texas red-anti rabbit IgG Mol. Probes goat 1:1000  
Table 6. List of secondary antibodies. 
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